menu
    • menu
    [{"orgOrder":0,"company":"Mirati Therapeutics","sponsor":"Sanofi","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Collaboration","leadProduct":"Adagrasib","moa":"||KRAS G12C","graph1":"Oncology","graph2":"IND Enabling","graph3":"Mirati Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Mirati Therapeutics \/ Sanofi","highestDevelopmentStatusID":"5","companyTruncated":"Mirati Therapeutics \/ Sanofi"},{"orgOrder":0,"company":"Focal Medical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2024","type":"Inapplicable","leadProduct":"Gemcitabine","moa":"DNA cross-linking","graph1":"Oncology","graph2":"IND Enabling","graph3":"Focal Medical","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Implant","sponsorNew":"Focal Medical \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Focal Medical \/ Inapplicable"},{"orgOrder":0,"company":"Ivy Brain Tumor Center","sponsor":"GSK","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2021","type":"Collaboration","leadProduct":"Niraparib Tosylate","moa":"PARP-1\/2","graph1":"Oncology","graph2":"IND Enabling","graph3":"Ivy Brain Tumor Center","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Ivy Brain Tumor Center \/ GSK","highestDevelopmentStatusID":"5","companyTruncated":"Ivy Brain Tumor Center \/ GSK"},{"orgOrder":0,"company":"PanTher Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2024","type":"Inapplicable","leadProduct":"Paclitaxel","moa":"Microtubule depolymerization","graph1":"Oncology","graph2":"IND Enabling","graph3":"PanTher Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"PanTher Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"PanTher Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Privo Technologies","sponsor":"The Division of Cancer Treatment and Diagnosis","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2022","type":"Funding","leadProduct":"Cisplatin","moa":"DNA","graph1":"Oncology","graph2":"IND Enabling","graph3":"Privo Technologies","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Privo Technologies \/ The Division of Cancer Treatment and Diagnosis","highestDevelopmentStatusID":"5","companyTruncated":"Privo Technologies \/ The Division of Cancer Treatment and Diagnosis"},{"orgOrder":0,"company":"ImmunityBio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"Nogapendekin Alpha Inbakicept","moa":"||IL-15-alpha receptor","graph1":"Oncology","graph2":"IND Enabling","graph3":"ImmunityBio","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ImmunityBio \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"ImmunityBio \/ Inapplicable"},{"orgOrder":0,"company":"ImmunityBio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"Nogapendekin Alpha Inbakicept","moa":"||IL-15-alpha receptor","graph1":"Oncology","graph2":"IND Enabling","graph3":"ImmunityBio","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ImmunityBio \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"ImmunityBio \/ Inapplicable"},{"orgOrder":0,"company":"ImmunityBio","sponsor":"Serum Institute of India","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2024","type":"Agreement","leadProduct":"Nogapendekin Alpha Inbakicept","moa":"||IL-15-alpha receptor","graph1":"Oncology","graph2":"IND Enabling","graph3":"ImmunityBio","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravesical Solution","sponsorNew":"ImmunityBio \/ Serum Institute of India","highestDevelopmentStatusID":"5","companyTruncated":"ImmunityBio \/ Serum Institute of India"},{"orgOrder":0,"company":"MAIA Biotechnology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Ateganosine","moa":"||Telomere","graph1":"Oncology","graph2":"IND Enabling","graph3":"MAIA Biotechnology","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intraperitoneal Injection","sponsorNew":"MAIA Biotechnology \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"MAIA Biotechnology \/ Inapplicable"},{"orgOrder":0,"company":"MAIA Biotechnology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Ateganosine","moa":"Telomere","graph1":"Oncology","graph2":"IND Enabling","graph3":"MAIA Biotechnology","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intraperitoneal Injection","sponsorNew":"MAIA Biotechnology \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"MAIA Biotechnology \/ Inapplicable"},{"orgOrder":0,"company":"Multitude Therapeutics","sponsor":"Adcendo","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2024","type":"Licensing Agreement","leadProduct":"ADCE-T02","moa":"Tissue factor","graph1":"Oncology","graph2":"IND Enabling","graph3":"Multitude Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Multitude Therapeutics \/ Adcendo","highestDevelopmentStatusID":"5","companyTruncated":"Multitude Therapeutics \/ Adcendo"},{"orgOrder":0,"company":"Asher Biotherapeutics","sponsor":"AstraZeneca","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2025","type":"Agreement","leadProduct":"Etakafusp Alpha","moa":"||CD8","graph1":"Oncology","graph2":"IND Enabling","graph3":"Asher Biotherapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Asher Biotherapeutics \/ AstraZeneca","highestDevelopmentStatusID":"5","companyTruncated":"Asher Biotherapeutics \/ AstraZeneca"},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Checkmate Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Large Molecule","year":"2021","type":"Collaboration","leadProduct":"Vidutolimod","moa":"||Toll-like-9 receptor","graph1":"Oncology","graph2":"IND Enabling","graph3":"Regeneron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Regeneron Pharmaceuticals \/ Checkmate Pharmaceuticals","highestDevelopmentStatusID":"5","companyTruncated":"Regeneron Pharmaceuticals \/ Checkmate Pharmaceuticals"},{"orgOrder":0,"company":"Prevail Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"PR001","moa":"GBA1","graph1":"Oncology","graph2":"IND Enabling","graph3":"Prevail Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Prevail Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Prevail Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Shenzhen Chipscreen Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Chiauranib","moa":"||VEGF receptor","graph1":"Oncology","graph2":"IND Enabling","graph3":"Shenzhen Chipscreen Biosciences","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Shenzhen Chipscreen Biosciences \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Shenzhen Chipscreen Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"BioAtla","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"BA3182","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"BioAtla","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"BioAtla \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"BioAtla \/ Inapplicable"},{"orgOrder":0,"company":"Atavistik Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"ATV-1601","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"Atavistik Bio","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Atavistik Bio \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Atavistik Bio \/ Inapplicable"},{"orgOrder":0,"company":"Hinova","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"HP518","moa":"Androgen receptor","graph1":"Oncology","graph2":"IND Enabling","graph3":"Hinova","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hinova \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Hinova \/ Inapplicable"},{"orgOrder":0,"company":"CSPC Pharmaceutical Group","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"SYS6020","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"CSPC Pharmaceutical Group","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"CSPC Pharmaceutical Group \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"CSPC Pharmaceutical Group \/ Inapplicable"},{"orgOrder":0,"company":"Genome & Company","sponsor":"Merck & Co","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Microorganism","year":"2022","type":"Collaboration","leadProduct":"GEN-001","moa":"||IL-7 receptor","graph1":"Oncology","graph2":"IND Enabling","graph3":"Genome & Company","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Genome & Company \/ Merck & Co","highestDevelopmentStatusID":"5","companyTruncated":"Genome & Company \/ Merck & Co"},{"orgOrder":0,"company":"Biddle Sawyer Corporation","sponsor":"TAE Life Sciences","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Large Molecule","year":"2023","type":"Agreement","leadProduct":"TC-220","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"Biddle Sawyer Corporation","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Biddle Sawyer Corporation \/ TAE Life Sciences","highestDevelopmentStatusID":"5","companyTruncated":"Biddle Sawyer Corporation \/ TAE Life Sciences"},{"orgOrder":0,"company":"Plus Therapeutics","sponsor":"United States Department of Defense","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Radiolabelled Compounds","year":"2024","type":"Funding","leadProduct":"186-Re Obisbemeda","moa":"Beta-radiation","graph1":"Oncology","graph2":"IND Enabling","graph3":"Plus Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Infusion","sponsorNew":"Plus Therapeutics \/ United States Department of Defense","highestDevelopmentStatusID":"5","companyTruncated":"Plus Therapeutics \/ United States Department of Defense"},{"orgOrder":0,"company":"Ideaya Biosciences","sponsor":"GSK","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"IDE705","moa":"||Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"Ideaya Biosciences","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ideaya Biosciences \/ GSK","highestDevelopmentStatusID":"5","companyTruncated":"Ideaya Biosciences \/ GSK"},{"orgOrder":0,"company":"Tango Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"TNG348","moa":"||USP-1","graph1":"Oncology","graph2":"IND Enabling","graph3":"Tango Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Tango Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Tango Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Accent Therapeutics","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Series C Financing","leadProduct":"ATX-968","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"Accent Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Accent Therapeutics \/ Bristol Myers Squibb","highestDevelopmentStatusID":"5","companyTruncated":"Accent Therapeutics \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"Olema Oncology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"OP-3136","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"Olema Oncology","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Olema Oncology \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Olema Oncology \/ Inapplicable"},{"orgOrder":0,"company":"Olema Oncology","sponsor":"Aurigene","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"OP-3136","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"Olema Oncology","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Olema Oncology \/ Aurigene","highestDevelopmentStatusID":"5","companyTruncated":"Olema Oncology \/ Aurigene"},{"orgOrder":0,"company":"Ensem Therapeutics","sponsor":"BeiGene","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Licensing Agreement","leadProduct":"ETX-197","moa":"CDK2","graph1":"Oncology","graph2":"IND Enabling","graph3":"Ensem Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Ensem Therapeutics \/ BeiGene","highestDevelopmentStatusID":"5","companyTruncated":"Ensem Therapeutics \/ BeiGene"},{"orgOrder":0,"company":"Laekna Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Afuresertib","moa":"||Pan-AKT","graph1":"Oncology","graph2":"IND Enabling","graph3":"Laekna Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Laekna Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Laekna Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Artiva Biotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"AB-201","moa":"Tissue factor","graph1":"Oncology","graph2":"IND Enabling","graph3":"Artiva Biotherapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Artiva Biotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Artiva Biotherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Amunix","sponsor":"Sanofi","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Acquisition","leadProduct":"AMX-818","moa":"Dysregulated protease","graph1":"Oncology","graph2":"IND Enabling","graph3":"Amunix","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Amunix \/ Sanofi","highestDevelopmentStatusID":"5","companyTruncated":"Amunix \/ Sanofi"},{"orgOrder":0,"company":"Amunix","sponsor":"Sanofi","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Acquisition","leadProduct":"AMX-818","moa":"Dysregulated protease","graph1":"Oncology","graph2":"IND Enabling","graph3":"Amunix","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Amunix \/ Sanofi","highestDevelopmentStatusID":"5","companyTruncated":"Amunix \/ Sanofi"},{"orgOrder":0,"company":"Therapeutic Solutions","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"StemVacs-V","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"Therapeutic Solutions","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Therapeutic Solutions \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Therapeutic Solutions \/ Inapplicable"},{"orgOrder":0,"company":"Repare Therapeutics","sponsor":"Ono Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CANADA","productType":"Other Small Molecule","year":"2023","type":"Partnership","leadProduct":"RP-2119","moa":"Pol-theta","graph1":"Oncology","graph2":"IND Enabling","graph3":"Repare Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Repare Therapeutics \/ Ono Pharmaceutical","highestDevelopmentStatusID":"5","companyTruncated":"Repare Therapeutics \/ Ono Pharmaceutical"},{"orgOrder":0,"company":"Adagene Suzhou Limited","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"ADG138","moa":"HER2\/CD3","graph1":"Oncology","graph2":"IND Enabling","graph3":"Adagene Suzhou Limited","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Adagene Suzhou Limited \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Adagene Suzhou Limited \/ Inapplicable"},{"orgOrder":0,"company":"GeneQuantum Healthcare","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody-drug Conjugate","year":"2022","type":"Inapplicable","leadProduct":"GQ1005","moa":"HER2","graph1":"Oncology","graph2":"IND Enabling","graph3":"GeneQuantum Healthcare","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"GeneQuantum Healthcare \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"GeneQuantum Healthcare \/ Inapplicable"},{"orgOrder":0,"company":"Carrick Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"IRELAND","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"CT7439","moa":"CDK12\/13","graph1":"Oncology","graph2":"IND Enabling","graph3":"Carrick Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Carrick Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Carrick Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Orum Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2022","type":"Inapplicable","leadProduct":"ORM-5029","moa":"E3 ubiquitin ligase pathway","graph1":"Oncology","graph2":"IND Enabling","graph3":"Orum Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Orum Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Orum Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Orum Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2022","type":"Inapplicable","leadProduct":"ORM-5029","moa":"E3 ubiquitin ligase pathway","graph1":"Oncology","graph2":"IND Enabling","graph3":"Orum Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Orum Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Orum Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Scorpion Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"STX-478","moa":"PI3K-alpha","graph1":"Oncology","graph2":"IND Enabling","graph3":"Scorpion Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Scorpion Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Scorpion Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Scorpion Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"STX-478","moa":"PI3K-alpha","graph1":"Oncology","graph2":"IND Enabling","graph3":"Scorpion Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Scorpion Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Scorpion Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"TransCode Therapeutics","sponsor":"H.C. Wainwright & Co","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Oligonucleotide","year":"2023","type":"Public Offering","leadProduct":"TTX-MC138","moa":"miR-10b","graph1":"Oncology","graph2":"IND Enabling","graph3":"TransCode Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"TransCode Therapeutics \/ H.C. Wainwright & Co","highestDevelopmentStatusID":"5","companyTruncated":"TransCode Therapeutics \/ H.C. Wainwright & Co"},{"orgOrder":0,"company":"TransCode Therapeutics","sponsor":"H.C. Wainwright & Co","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Oligonucleotide","year":"2023","type":"Public Offering","leadProduct":"TTX-MC138","moa":"miR-10b","graph1":"Oncology","graph2":"IND Enabling","graph3":"TransCode Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"TransCode Therapeutics \/ H.C. Wainwright & Co","highestDevelopmentStatusID":"5","companyTruncated":"TransCode Therapeutics \/ H.C. Wainwright & Co"},{"orgOrder":0,"company":"TransCode Therapeutics","sponsor":"National Institutes of Health","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Oligonucleotide","year":"2023","type":"Funding","leadProduct":"TTX-MC138","moa":"miR-10b","graph1":"Oncology","graph2":"IND Enabling","graph3":"TransCode Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"TransCode Therapeutics \/ National Institutes of Health","highestDevelopmentStatusID":"5","companyTruncated":"TransCode Therapeutics \/ National Institutes of Health"},{"orgOrder":0,"company":"IASO Bio","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"CT120","moa":"CD19\/22","graph1":"Oncology","graph2":"IND Enabling","graph3":"IASO Bio","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"IASO Bio \/ Merck & Co","highestDevelopmentStatusID":"5","companyTruncated":"IASO Bio \/ Merck & Co"},{"orgOrder":0,"company":"Sirnaomics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Oligonucleotide","year":"2020","type":"Inapplicable","leadProduct":"Cotsiranib","moa":"TGF-beta-1\/COX-2","graph1":"Oncology","graph2":"IND Enabling","graph3":"Sirnaomics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"Sirnaomics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Sirnaomics \/ Inapplicable"},{"orgOrder":0,"company":"Immune-Onc Therapeutics","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Collaboration","leadProduct":"Atezolizumab","moa":"||LILRB2","graph1":"Oncology","graph2":"IND Enabling","graph3":"Immune-Onc Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Immune-Onc Therapeutics \/ F. Hoffmann-La Roche","highestDevelopmentStatusID":"5","companyTruncated":"Immune-Onc Therapeutics \/ F. Hoffmann-La Roche"},{"orgOrder":0,"company":"RayzeBio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"RayzeBio","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"RayzeBio \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"RayzeBio \/ Inapplicable"},{"orgOrder":0,"company":"RayzeBio","sponsor":"J.P. Morgan","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Peptide","year":"2023","type":"Public Offering","leadProduct":"225-Ac","moa":"||Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"RayzeBio","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"RayzeBio \/ J.P. Morgan","highestDevelopmentStatusID":"5","companyTruncated":"RayzeBio \/ J.P. Morgan"},{"orgOrder":0,"company":"Kintara Therapeutics","sponsor":"TuHURA Biosciences","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2024","type":"Merger","leadProduct":"IFx-Hu2.0","moa":"||Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"Kintara Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intralesional Injection","sponsorNew":"Kintara Therapeutics \/ TuHURA Biosciences","highestDevelopmentStatusID":"5","companyTruncated":"Kintara Therapeutics \/ TuHURA Biosciences"},{"orgOrder":0,"company":"Seneca Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Microorganism","year":"2022","type":"Inapplicable","leadProduct":"SVV-001","moa":"TEM8","graph1":"Oncology","graph2":"IND Enabling","graph3":"Seneca Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Seneca Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Seneca Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Oryzon Genomics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SPAIN","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Iadademstat","moa":"LSD1","graph1":"Oncology","graph2":"IND Enabling","graph3":"Oryzon Genomics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Oryzon Genomics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Oryzon Genomics \/ Inapplicable"},{"orgOrder":0,"company":"Abdera Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Radiolabelled Compounds","year":"2024","type":"Inapplicable","leadProduct":"ABD-147","moa":"Alpha-radiation","graph1":"Oncology","graph2":"IND Enabling","graph3":"Abdera Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Abdera Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Abdera Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"NeoImmuneTech","sponsor":"Genentech","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Atezolizumab","moa":"||IL-7 receptor","graph1":"Oncology","graph2":"IND Enabling","graph3":"NeoImmuneTech","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"NeoImmuneTech \/ Genentech","highestDevelopmentStatusID":"5","companyTruncated":"NeoImmuneTech \/ Genentech"},{"orgOrder":0,"company":"Everest Medicines","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2025","type":"Inapplicable","leadProduct":"EVM14","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"Everest Medicines","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Everest Medicines \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Everest Medicines \/ Inapplicable"},{"orgOrder":0,"company":"Humedix","sponsor":"Kineta","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Antibody","year":"2021","type":"Partnership","leadProduct":"KVA12.1","moa":"VISTA","graph1":"Oncology","graph2":"IND Enabling","graph3":"Humedix","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Humedix \/ Kineta","highestDevelopmentStatusID":"5","companyTruncated":"Humedix \/ Kineta"},{"orgOrder":0,"company":"Omega Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"OTX-2101","moa":"c-Myc cell proliferation","graph1":"Oncology","graph2":"IND Enabling","graph3":"Omega Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Omega Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Omega Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Yumanity Therapeutics","sponsor":"Kineta","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Merger","leadProduct":"KVA12.1","moa":"VISTA","graph1":"Oncology","graph2":"IND Enabling","graph3":"Yumanity Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Yumanity Therapeutics \/ Kineta","highestDevelopmentStatusID":"5","companyTruncated":"Yumanity Therapeutics \/ Kineta"},{"orgOrder":0,"company":"ABVC BioPharma","sponsor":"BIOKEY","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"BLEX 404","moa":"||Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"ABVC BioPharma","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"ABVC BioPharma \/ BIOKEY","highestDevelopmentStatusID":"5","companyTruncated":"ABVC BioPharma \/ BIOKEY"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"BridgeBio Pharma","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Collaboration","leadProduct":"BBP-398","moa":"||SHP2","graph1":"Oncology","graph2":"IND Enabling","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Bristol Myers Squibb \/ BridgeBio Pharma","highestDevelopmentStatusID":"5","companyTruncated":"Bristol Myers Squibb \/ BridgeBio Pharma"},{"orgOrder":0,"company":"Laekna Therapeutics","sponsor":"Innovent Biologics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Afuresertib","moa":"||Pan-AKT","graph1":"Oncology","graph2":"IND Enabling","graph3":"Laekna Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Laekna Therapeutics \/ Innovent Biologics","highestDevelopmentStatusID":"5","companyTruncated":"Laekna Therapeutics \/ Innovent Biologics"},{"orgOrder":0,"company":"RedCloud Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"H002","moa":"EGFR","graph1":"Oncology","graph2":"IND Enabling","graph3":"RedCloud Bio","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"RedCloud Bio \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"RedCloud Bio \/ Inapplicable"},{"orgOrder":0,"company":"RedCloud Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"H002","moa":"EGFR","graph1":"Oncology","graph2":"IND Enabling","graph3":"RedCloud Bio","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"RedCloud Bio \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"RedCloud Bio \/ Inapplicable"},{"orgOrder":0,"company":"Pierre Fabre","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Other Large Molecule","year":"2024","type":"Inapplicable","leadProduct":"PFL-002","moa":"c-Met receptor","graph1":"Oncology","graph2":"IND Enabling","graph3":"Pierre Fabre","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pierre Fabre \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Pierre Fabre \/ Inapplicable"},{"orgOrder":0,"company":"Nuvalent","sponsor":"Deerfield Management","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Series A Financing","leadProduct":"NUV-520","moa":"ROS1 receptor","graph1":"Oncology","graph2":"IND Enabling","graph3":"Nuvalent","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Nuvalent \/ Deerfield Management","highestDevelopmentStatusID":"5","companyTruncated":"Nuvalent \/ Deerfield Management"},{"orgOrder":0,"company":"Theseus Pharmaceuticals","sponsor":"Concentra Biosciences","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Acquisition","leadProduct":"THE-349","moa":"EGFR","graph1":"Oncology","graph2":"IND Enabling","graph3":"Theseus Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Theseus Pharmaceuticals \/ Concentra Biosciences","highestDevelopmentStatusID":"5","companyTruncated":"Theseus Pharmaceuticals \/ Concentra Biosciences"},{"orgOrder":0,"company":"Theseus Pharmaceuticals","sponsor":"Concentra Biosciences","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Acquisition","leadProduct":"THE-349","moa":"EGFR","graph1":"Oncology","graph2":"IND Enabling","graph3":"Theseus Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Theseus Pharmaceuticals \/ Concentra Biosciences","highestDevelopmentStatusID":"5","companyTruncated":"Theseus Pharmaceuticals \/ Concentra Biosciences"},{"orgOrder":0,"company":"Theseus Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"THE-349","moa":"EGFR","graph1":"Oncology","graph2":"IND Enabling","graph3":"Theseus Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Theseus Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Theseus Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Theseus Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"THE-349","moa":"EGFR","graph1":"Oncology","graph2":"IND Enabling","graph3":"Theseus Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Theseus Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Theseus Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Ocean Biomedical","sponsor":"Aesther Healthcare","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Agreement","leadProduct":"OCX-253","moa":"CHI3L1","graph1":"Oncology","graph2":"IND Enabling","graph3":"Ocean Biomedical","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ocean Biomedical \/ Aesther Healthcare","highestDevelopmentStatusID":"5","companyTruncated":"Ocean Biomedical \/ Aesther Healthcare"},{"orgOrder":0,"company":"Ocean Biomedical","sponsor":"Aesther Healthcare","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Merger","leadProduct":"OCX-253","moa":"CHI3L1","graph1":"Oncology","graph2":"IND Enabling","graph3":"Ocean Biomedical","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ocean Biomedical \/ Aesther Healthcare","highestDevelopmentStatusID":"5","companyTruncated":"Ocean Biomedical \/ Aesther Healthcare"},{"orgOrder":0,"company":"Ocean Biomedical","sponsor":"Aesther Healthcare Acquisition Corp","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Agreement","leadProduct":"OCX-253","moa":"CHI3L1","graph1":"Oncology","graph2":"IND Enabling","graph3":"Ocean Biomedical","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ocean Biomedical \/ Aesther Healthcare Acquisition Corp","highestDevelopmentStatusID":"5","companyTruncated":"Ocean Biomedical \/ Aesther Healthcare Acquisition Corp"},{"orgOrder":0,"company":"Ocean Biomedical","sponsor":"Maxim Group LLC","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Private Placement","leadProduct":"OCX-253","moa":"CHI3L1","graph1":"Oncology","graph2":"IND Enabling","graph3":"Ocean Biomedical","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ocean Biomedical \/ Maxim Group LLC","highestDevelopmentStatusID":"5","companyTruncated":"Ocean Biomedical \/ Maxim Group LLC"},{"orgOrder":0,"company":"GSK","sponsor":"Zentalis Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2021","type":"Collaboration","leadProduct":"Azenosertib","moa":"||WEE1","graph1":"Oncology","graph2":"IND Enabling","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"GSK \/ Zentalis Pharmaceuticals","highestDevelopmentStatusID":"5","companyTruncated":"GSK \/ Zentalis Pharmaceuticals"},{"orgOrder":0,"company":"Aveo Oncology","sponsor":"NiKang Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Collaboration","leadProduct":"NKT2152","moa":"||HIF-2-alpha","graph1":"Oncology","graph2":"IND Enabling","graph3":"Aveo Oncology","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Aveo Oncology \/ NiKang Therapeutics","highestDevelopmentStatusID":"5","companyTruncated":"Aveo Oncology \/ NiKang Therapeutics"},{"orgOrder":0,"company":"Phio Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Oligonucleotide","year":"2022","type":"Inapplicable","leadProduct":"PH-762","moa":"PD-L1","graph1":"Oncology","graph2":"IND Enabling","graph3":"Phio Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Phio Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Phio Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Phio Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Oligonucleotide","year":"2023","type":"Inapplicable","leadProduct":"PH-762","moa":"PD-L1","graph1":"Oncology","graph2":"IND Enabling","graph3":"Phio Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Phio Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Phio Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Alpha Tau Medical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Radium-224","moa":"Alpha-radiation","graph1":"Oncology","graph2":"IND Enabling","graph3":"Alpha Tau Medical","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Alpha Tau Medical \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Alpha Tau Medical \/ Inapplicable"},{"orgOrder":0,"company":"Alpha Tau Medical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Radium-224","moa":"Alpha-radiation","graph1":"Oncology","graph2":"IND Enabling","graph3":"Alpha Tau Medical","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Alpha Tau Medical \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Alpha Tau Medical \/ Inapplicable"},{"orgOrder":0,"company":"Senti Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"SENTI-202","moa":"CD33\/FLT3","graph1":"Oncology","graph2":"IND Enabling","graph3":"Senti Biosciences","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Senti Biosciences \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Senti Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"GT Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"GTB-3650","moa":"CD33","graph1":"Oncology","graph2":"IND Enabling","graph3":"GT Biopharma","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"GT Biopharma \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"GT Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"Y-mAbs Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"177-Lu Omburtamab-DTPA","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"Y-mAbs Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Y-mAbs Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Y-mAbs Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Sirnaomics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Oligonucleotide","year":"2020","type":"Inapplicable","leadProduct":"Cotsiranib","moa":"TGF-beta-1\/COX-2","graph1":"Oncology","graph2":"IND Enabling","graph3":"Sirnaomics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Sirnaomics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Sirnaomics \/ Inapplicable"},{"orgOrder":0,"company":"PeptiDream","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Other Large Molecule","year":"2024","type":"Inapplicable","leadProduct":"PD-29875","moa":"CLDN18.2","graph1":"Oncology","graph2":"IND Enabling","graph3":"PeptiDream","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"PeptiDream \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"PeptiDream \/ Inapplicable"},{"orgOrder":0,"company":"Alentis Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Other Large Molecule","year":"2023","type":"Inapplicable","leadProduct":"ALE.C04","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"Alentis Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Alentis Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Alentis Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Alentis Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Other Large Molecule","year":"2024","type":"Inapplicable","leadProduct":"ALE.P02","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"Alentis Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Alentis Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Alentis Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Alentis Therapeutics","sponsor":"OrbiMed Advisors","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Other Large Molecule","year":"2024","type":"Series D Financing","leadProduct":"ALE.P02","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"Alentis Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Alentis Therapeutics \/ OrbiMed Advisors","highestDevelopmentStatusID":"5","companyTruncated":"Alentis Therapeutics \/ OrbiMed Advisors"},{"orgOrder":0,"company":"Axcynsis Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SINGAPORE","productType":"Antibody-drug Conjugate","year":"2025","type":"Inapplicable","leadProduct":"AT03-65","moa":"CLDN-6","graph1":"Oncology","graph2":"IND Enabling","graph3":"Axcynsis Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Axcynsis Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Axcynsis Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Context Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"CTIM-76","moa":"CLDN-6\/CD3","graph1":"Oncology","graph2":"IND Enabling","graph3":"Context Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Context Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Context Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Context Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"CTIM-76","moa":"CLDN-6\/CD3","graph1":"Oncology","graph2":"IND Enabling","graph3":"Context Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Context Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Context Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Context Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"CTIM-76","moa":"CLDN-6\/CD3","graph1":"Oncology","graph2":"IND Enabling","graph3":"Context Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Context Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Context Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Avelos Therapeutics","sponsor":"Stassets Investment","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Other Small Molecule","year":"2024","type":"Series B Financing","leadProduct":"AD1208","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"Avelos Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Avelos Therapeutics \/ Stassets Investment","highestDevelopmentStatusID":"5","companyTruncated":"Avelos Therapeutics \/ Stassets Investment"},{"orgOrder":0,"company":"Neogap","sponsor":"Karolinska University Hospital","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"Neogap","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Neogap \/ Karolinska University Hospital","highestDevelopmentStatusID":"5","companyTruncated":"Neogap \/ Karolinska University Hospital"},{"orgOrder":0,"company":"Carina Biotech","sponsor":"Tenmile","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Undisclosed","year":"2022","type":"Financing","leadProduct":"Undisclosed","moa":"LGR5","graph1":"Oncology","graph2":"IND Enabling","graph3":"Carina Biotech","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Carina Biotech \/ Tenmile","highestDevelopmentStatusID":"5","companyTruncated":"Carina Biotech \/ Tenmile"},{"orgOrder":0,"company":"Fusion Pharma","sponsor":"Ipsen","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"FPI-2059","moa":"Neurotensin type-1 receptor","graph1":"Oncology","graph2":"IND Enabling","graph3":"Fusion Pharma","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Fusion Pharma \/ Ipsen","highestDevelopmentStatusID":"5","companyTruncated":"Fusion Pharma \/ Ipsen"},{"orgOrder":0,"company":"TG ImmunoPharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Large Molecule","year":"2023","type":"Inapplicable","leadProduct":"TGI-6","moa":"CD3","graph1":"Oncology","graph2":"IND Enabling","graph3":"TG ImmunoPharma","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"TG ImmunoPharma \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"TG ImmunoPharma \/ Inapplicable"},{"orgOrder":0,"company":"TG ImmunoPharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Large Molecule","year":"2023","type":"Inapplicable","leadProduct":"TGI-6","moa":"CD3","graph1":"Oncology","graph2":"IND Enabling","graph3":"TG ImmunoPharma","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"TG ImmunoPharma \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"TG ImmunoPharma \/ Inapplicable"},{"orgOrder":0,"company":"Gnubiotics Sciences","sponsor":"University of Zurich","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Peptide","year":"2022","type":"Inapplicable","leadProduct":"GCX","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"Gnubiotics Sciences","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Gnubiotics Sciences \/ University of Zurich","highestDevelopmentStatusID":"5","companyTruncated":"Gnubiotics Sciences \/ University of Zurich"},{"orgOrder":0,"company":"Actimed Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"S-Pindolol Benzoate","moa":"5-HTA1a\/beta-1 receptor","graph1":"Oncology","graph2":"IND Enabling","graph3":"Actimed Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Actimed Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Actimed Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"CV6 Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"5 Fluorouracil","moa":"||dUTPase","graph1":"Oncology","graph2":"IND Enabling","graph3":"CV6 Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"CV6 Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"CV6 Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Aprea Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"APR-1051","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"Aprea Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Aprea Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Aprea Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Signet","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"INDIA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"sigx1094","moa":"FAK\/YAP","graph1":"Oncology","graph2":"IND Enabling","graph3":"Signet","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Signet \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Signet \/ Inapplicable"},{"orgOrder":0,"company":"Circle Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Peptide","year":"2024","type":"Inapplicable","leadProduct":"CID-078","moa":"Cyclin A\/Cyclin B RxL","graph1":"Oncology","graph2":"IND Enabling","graph3":"Circle Pharma","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Circle Pharma \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Circle Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Chengdu Weisijin Biomedical Technology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Vaccine","year":"2024","type":"Inapplicable","leadProduct":"WGc-043","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"Chengdu Weisijin Biomedical Technology","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Chengdu Weisijin Biomedical Technology \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Chengdu Weisijin Biomedical Technology \/ Inapplicable"},{"orgOrder":0,"company":"Chengdu Weisijin Biomedical Technology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Vaccine","year":"2024","type":"Inapplicable","leadProduct":"WGc-043","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"Chengdu Weisijin Biomedical Technology","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Chengdu Weisijin Biomedical Technology \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Chengdu Weisijin Biomedical Technology \/ Inapplicable"},{"orgOrder":0,"company":"Acepodia","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"TAIWAN","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"ACE2016","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"Acepodia","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Acepodia \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Acepodia \/ Inapplicable"},{"orgOrder":0,"company":"InnoCare Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Furmonertinib","moa":"||SHP2","graph1":"Oncology","graph2":"IND Enabling","graph3":"InnoCare Pharma","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"InnoCare Pharma \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"InnoCare Pharma \/ Inapplicable"},{"orgOrder":0,"company":"BioCity Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Large Molecule","year":"2023","type":"Inapplicable","leadProduct":"BC3448","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"BioCity Biopharma","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"BioCity Biopharma \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"BioCity Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"Alterome Therapeutics","sponsor":"Goldman Sachs & Co","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Series B Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"Alterome Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Alterome Therapeutics \/ Goldman Sachs & Co","highestDevelopmentStatusID":"5","companyTruncated":"Alterome Therapeutics \/ Goldman Sachs & Co"},{"orgOrder":0,"company":"Ideaya Biosciences","sponsor":"GSK","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"Ideaya Biosciences","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ideaya Biosciences \/ GSK","highestDevelopmentStatusID":"5","companyTruncated":"Ideaya Biosciences \/ GSK"},{"orgOrder":0,"company":"Immunofoco","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"IMC-001","moa":"PD-L1","graph1":"Oncology","graph2":"IND Enabling","graph3":"Immunofoco","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Immunofoco \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Immunofoco \/ Inapplicable"},{"orgOrder":0,"company":"Insilico Medicine","sponsor":"Stemline Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"HONG KONG","productType":"Undisclosed","year":"2024","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"Insilico Medicine","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Insilico Medicine \/ Stemline Therapeutics","highestDevelopmentStatusID":"5","companyTruncated":"Insilico Medicine \/ Stemline Therapeutics"},{"orgOrder":0,"company":"ORIC Pharmaceuticals","sponsor":"Johnson & Johnson Innovative Medicine","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Agreement","leadProduct":"Amivantamab","moa":"||EGFR","graph1":"Oncology","graph2":"IND Enabling","graph3":"ORIC Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"ORIC Pharmaceuticals \/ Johnson & Johnson Innovative Medicine","highestDevelopmentStatusID":"5","companyTruncated":"ORIC Pharmaceuticals \/ Johnson & Johnson Innovative Medicine"},{"orgOrder":0,"company":"MediLink Therapeutics","sponsor":"Amgen Inc","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Large Molecule","year":"2024","type":"Collaboration","leadProduct":"Tarlatamab","moa":"||Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"MediLink Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"MediLink Therapeutics \/ Amgen Inc","highestDevelopmentStatusID":"5","companyTruncated":"MediLink Therapeutics \/ Amgen Inc"},{"orgOrder":0,"company":"Asher Biotherapeutics","sponsor":"Amgen Inc","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2025","type":"Collaboration","leadProduct":"Etakafusp Alpha","moa":"||CD8","graph1":"Oncology","graph2":"IND Enabling","graph3":"Asher Biotherapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Asher Biotherapeutics \/ Amgen Inc","highestDevelopmentStatusID":"5","companyTruncated":"Asher Biotherapeutics \/ Amgen Inc"},{"orgOrder":0,"company":"Oryzon Genomics","sponsor":"European Commission","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SPAIN","productType":"Other Small Molecule","year":"2022","type":"Funding","leadProduct":"Iadademstat","moa":"||LSD1","graph1":"Oncology","graph2":"IND Enabling","graph3":"Oryzon Genomics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Oryzon Genomics \/ European Commission","highestDevelopmentStatusID":"5","companyTruncated":"Oryzon Genomics \/ European Commission"},{"orgOrder":0,"company":"Chimeric Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"CHM 2101","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"Chimeric Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Chimeric Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Chimeric Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Lantern Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Irofulven","moa":"DNA adduct","graph1":"Oncology","graph2":"IND Enabling","graph3":"Lantern Pharma","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Lantern Pharma \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Lantern Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Lantern Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Irofulven","moa":"DNA adduct","graph1":"Oncology","graph2":"IND Enabling","graph3":"Lantern Pharma","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Lantern Pharma \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Lantern Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Lantern Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Irofulven","moa":"DNA adduct","graph1":"Oncology","graph2":"IND Enabling","graph3":"Lantern Pharma","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Lantern Pharma \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Lantern Pharma \/ Inapplicable"},{"orgOrder":0,"company":"CytoImmune Therapeutics","sponsor":"Cytovia Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Acquisition","leadProduct":"CYT-101","moa":"Dual EGFR","graph1":"Oncology","graph2":"IND Enabling","graph3":"CytoImmune Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intracranial Injection","sponsorNew":"CytoImmune Therapeutics \/ Cytovia Therapeutics","highestDevelopmentStatusID":"5","companyTruncated":"CytoImmune Therapeutics \/ Cytovia Therapeutics"},{"orgOrder":0,"company":"Kairos Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"KROS-201","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"Kairos Pharma","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Kairos Pharma \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Kairos Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Jubilant Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"JBI-778","moa":"PRMT5","graph1":"Oncology","graph2":"IND Enabling","graph3":"Jubilant Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Jubilant Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Jubilant Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Moleculin Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"WP1122","moa":"Glycolysis","graph1":"Oncology","graph2":"IND Enabling","graph3":"Moleculin Biotech","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Moleculin Biotech \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Moleculin Biotech \/ Inapplicable"},{"orgOrder":0,"company":"Moleculin Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"WP1122","moa":"Glycolysis","graph1":"Oncology","graph2":"IND Enabling","graph3":"Moleculin Biotech","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Moleculin Biotech \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Moleculin Biotech \/ Inapplicable"},{"orgOrder":0,"company":"Ariceum Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"ATT001","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"Ariceum Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ariceum Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Ariceum Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Ariceum Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"ATT001","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"Ariceum Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ariceum Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Ariceum Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Myosin Therapeutics","sponsor":"DeepWork Capital","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Financing","leadProduct":"MT-125","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"Myosin Therapeutics","amount2":0.050000000000000003,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0.050000000000000003,"dosageForm":"Undisclosed","sponsorNew":"Myosin Therapeutics \/ DeepWork Capital","highestDevelopmentStatusID":"5","companyTruncated":"Myosin Therapeutics \/ DeepWork Capital"},{"orgOrder":0,"company":"Myosin Therapeutics","sponsor":"Mint12 Pharma","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Financing","leadProduct":"MT-125","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"Myosin Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Myosin Therapeutics \/ Mint12 Pharma","highestDevelopmentStatusID":"5","companyTruncated":"Myosin Therapeutics \/ Mint12 Pharma"},{"orgOrder":0,"company":"Adaptin Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"APTN-101","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"Adaptin Bio","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Adaptin Bio \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Adaptin Bio \/ Inapplicable"},{"orgOrder":0,"company":"City of Hope","sponsor":"Calidi Biotherapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Microorganism","year":"2021","type":"Collaboration","leadProduct":"Allogeneic Neural Stem Cell","moa":"||Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"City of Hope","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"City of Hope \/ Calidi Biotherapeutics","highestDevelopmentStatusID":"5","companyTruncated":"City of Hope \/ Calidi Biotherapeutics"},{"orgOrder":0,"company":"NeuExcell therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"NXL-004","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"NeuExcell therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"NeuExcell therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"NeuExcell therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Galectin Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GEORGIA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Belapectin","moa":"||Galectin-3","graph1":"Oncology","graph2":"IND Enabling","graph3":"Galectin Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Galectin Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Galectin Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Fusion Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"225-Ac Vofatamab","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"Fusion Pharma","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Fusion Pharma \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Fusion Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Fusion Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"225-Ac Vofatamab","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"Fusion Pharma","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Fusion Pharma \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Fusion Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Neuboron","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"P-Borono-L-Phenylalanine","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"Neuboron","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Neuboron \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Neuboron \/ Inapplicable"},{"orgOrder":0,"company":"TScan Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"TSC-203","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"TScan Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"TScan Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"TScan Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"SIRPant Immunotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"SI-101","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"SIRPant Immunotherapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"SIRPant Immunotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"SIRPant Immunotherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Eilean Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Balamenib","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"Eilean Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Eilean Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Eilean Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Pacylex Pharmaceuticals","sponsor":"Canadian Angel Investors","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CANADA","productType":"Other Small Molecule","year":"2020","type":"Financing","leadProduct":"PCLX-001","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"Pacylex Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Pacylex Pharmaceuticals \/ Canadian Angel Investors","highestDevelopmentStatusID":"5","companyTruncated":"Pacylex Pharmaceuticals \/ Canadian Angel Investors"},{"orgOrder":0,"company":"Zentalis Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"ZN-D5","moa":"BCL-2","graph1":"Oncology","graph2":"IND Enabling","graph3":"Zentalis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Zentalis Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Zentalis Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Salarius Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Deuterium Stabilized(S)-Avadomide","moa":"Cereblon","graph1":"Oncology","graph2":"IND Enabling","graph3":"Salarius Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Salarius Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Salarius Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Salarius Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Deuterium Stabilized(S)-Avadomide","moa":"Cereblon","graph1":"Oncology","graph2":"IND Enabling","graph3":"Salarius Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Salarius Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Salarius Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Salarius Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Deuterium Stabilized(S)-Avadomide","moa":"Cereblon","graph1":"Oncology","graph2":"IND Enabling","graph3":"Salarius Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Salarius Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Salarius Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Salarius Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Deuterium Stabilized(S)-Avadomide","moa":"Cereblon","graph1":"Oncology","graph2":"IND Enabling","graph3":"Salarius Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Salarius Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Salarius Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"GammaDelta Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"GDX012","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"GammaDelta Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"GammaDelta Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"GammaDelta Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Umoja Biopharma","sponsor":"AbbVie Inc","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Collaboration","leadProduct":"UB-VV111","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"Umoja Biopharma","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Umoja Biopharma \/ AbbVie Inc","highestDevelopmentStatusID":"5","companyTruncated":"Umoja Biopharma \/ AbbVie Inc"},{"orgOrder":0,"company":"Umoja Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"UB-VV111","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"Umoja Biopharma","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Umoja Biopharma \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Umoja Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"Iambic Therapeutics","sponsor":"Ascenta Capital","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Series B Financing","leadProduct":"IAM-H1","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"Iambic Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Iambic Therapeutics \/ Ascenta Capital","highestDevelopmentStatusID":"5","companyTruncated":"Iambic Therapeutics \/ Ascenta Capital"},{"orgOrder":0,"company":"Radiopharm Theranostics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Radiolabelled Compounds","year":"2024","type":"Inapplicable","leadProduct":"177-Lu RAD202","moa":"HER2","graph1":"Oncology","graph2":"IND Enabling","graph3":"Radiopharm Theranostics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Radiopharm Theranostics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Radiopharm Theranostics \/ Inapplicable"},{"orgOrder":0,"company":"NextPoint","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"NPX887","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"NextPoint","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"NextPoint \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"NextPoint \/ Inapplicable"},{"orgOrder":0,"company":"Rubius Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"RTX-321","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"Rubius Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Rubius Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Rubius Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Rubius Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"RTX-321","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"Rubius Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Rubius Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Rubius Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"SCG Cell Therapy","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SINGAPORE","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"SCG142","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"SCG Cell Therapy","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"SCG Cell Therapy \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"SCG Cell Therapy \/ Inapplicable"},{"orgOrder":0,"company":"Transgene","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"Tipapkinogen sovacivec","moa":"||Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"Transgene","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Transgene \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Transgene \/ Inapplicable"},{"orgOrder":0,"company":"XinThera","sponsor":"Gilead Sciences","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Acquisition","leadProduct":"XIN5104","moa":"PARP-1","graph1":"Oncology","graph2":"IND Enabling","graph3":"XinThera","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"XinThera \/ Gilead Sciences","highestDevelopmentStatusID":"5","companyTruncated":"XinThera \/ Gilead Sciences"},{"orgOrder":0,"company":"Medivir","sponsor":"Tango Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"TNG348","moa":"USP-1","graph1":"Oncology","graph2":"IND Enabling","graph3":"Medivir","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Medivir \/ Tango Therapeutics","highestDevelopmentStatusID":"5","companyTruncated":"Medivir \/ Tango Therapeutics"},{"orgOrder":0,"company":"Avenzo Therapeutics","sponsor":"Gilead Sciences","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Collaboration","leadProduct":"AVZO-021","moa":"||CDK2","graph1":"Oncology","graph2":"IND Enabling","graph3":"Avenzo Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Avenzo Therapeutics \/ Gilead Sciences","highestDevelopmentStatusID":"5","companyTruncated":"Avenzo Therapeutics \/ Gilead Sciences"},{"orgOrder":0,"company":"Quanta Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"QTX3034","moa":"Allosteric KRAS","graph1":"Oncology","graph2":"IND Enabling","graph3":"Quanta Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Quanta Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Quanta Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Anocca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"ANOC-001","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"Anocca","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Anocca \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Anocca \/ Inapplicable"},{"orgOrder":0,"company":"Elicio Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"ELI-002","moa":"KRAS","graph1":"Oncology","graph2":"IND Enabling","graph3":"Elicio Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Elicio Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Elicio Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"GenFleet Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"VS-7375","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"GenFleet Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"GenFleet Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"GenFleet Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Hookipa Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"HB-700","moa":"KRAS G12D","graph1":"Oncology","graph2":"IND Enabling","graph3":"Hookipa Pharma","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hookipa Pharma \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Hookipa Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Quanta Therapeutics","sponsor":"Avidity Partners","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Series D Financing","leadProduct":"QTX3034","moa":"Allosteric KRAS","graph1":"Oncology","graph2":"IND Enabling","graph3":"Quanta Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Quanta Therapeutics \/ Avidity Partners","highestDevelopmentStatusID":"5","companyTruncated":"Quanta Therapeutics \/ Avidity Partners"},{"orgOrder":0,"company":"Emendo Biotherapeutics","sponsor":"Anocca","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"Emendo Biotherapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Emendo Biotherapeutics \/ Anocca","highestDevelopmentStatusID":"5","companyTruncated":"Emendo Biotherapeutics \/ Anocca"},{"orgOrder":0,"company":"Poolbeg Pharma","sponsor":"Hookipa Pharma","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Cell and Gene therapy","year":"2025","type":"Merger","leadProduct":"HB-700","moa":"KRAS G12D","graph1":"Oncology","graph2":"IND Enabling","graph3":"Poolbeg Pharma","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Poolbeg Pharma \/ Hookipa Pharma","highestDevelopmentStatusID":"5","companyTruncated":"Poolbeg Pharma \/ Hookipa Pharma"},{"orgOrder":0,"company":"InnoCare Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Azacitidine","moa":"||BCL-2","graph1":"Oncology","graph2":"IND Enabling","graph3":"InnoCare Pharma","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"InnoCare Pharma \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"InnoCare Pharma \/ Inapplicable"},{"orgOrder":0,"company":"InnoCare Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Mesutoclax","moa":"||BCL-2","graph1":"Oncology","graph2":"IND Enabling","graph3":"InnoCare Pharma","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"InnoCare Pharma \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"InnoCare Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Fate Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"FT819","moa":"CAR19 T-cell","graph1":"Oncology","graph2":"IND Enabling","graph3":"Fate Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Fate Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Fate Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Lomond Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Lonitoclax","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"Lomond Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Lomond Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Lomond Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Poseida Therapeutics, Inc","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"P-CD19CD20-ALLO1","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"Poseida Therapeutics, Inc","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Poseida Therapeutics, Inc \/ F. Hoffmann-La Roche","highestDevelopmentStatusID":"5","companyTruncated":"Poseida Therapeutics, Inc \/ F. Hoffmann-La Roche"},{"orgOrder":0,"company":"Sana Biotechnology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"SC291","moa":"CD19","graph1":"Oncology","graph2":"IND Enabling","graph3":"Sana Biotechnology","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sana Biotechnology \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Sana Biotechnology \/ Inapplicable"},{"orgOrder":0,"company":"Sana Biotechnology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"SC262","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"Sana Biotechnology","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sana Biotechnology \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Sana Biotechnology \/ Inapplicable"},{"orgOrder":0,"company":"AB Science","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"AB8939","moa":"Tubulin","graph1":"Oncology","graph2":"IND Enabling","graph3":"AB Science","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AB Science \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"AB Science \/ Inapplicable"},{"orgOrder":0,"company":"AB Science","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"AB8939","moa":"Tubulin","graph1":"Oncology","graph2":"IND Enabling","graph3":"AB Science","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AB Science \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"AB Science \/ Inapplicable"},{"orgOrder":0,"company":"Kahr Medical","sponsor":"Cancer Focus Fund","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Protein","year":"2021","type":"Funding","leadProduct":"Azacytidine","moa":"||CD47\/41BB","graph1":"Oncology","graph2":"IND Enabling","graph3":"Kahr Medical","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Kahr Medical \/ Cancer Focus Fund","highestDevelopmentStatusID":"5","companyTruncated":"Kahr Medical \/ Cancer Focus Fund"},{"orgOrder":0,"company":"Cantargia AB","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Nadunolimab","moa":"IL-1-alpha receptor","graph1":"Oncology","graph2":"IND Enabling","graph3":"Cantargia AB","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Cantargia AB \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Cantargia AB \/ Inapplicable"},{"orgOrder":0,"company":"BioRay Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Large Molecule","year":"2023","type":"Inapplicable","leadProduct":"BR105","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"BioRay Pharmaceutical","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"BioRay Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"BioRay Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Escend Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"ES-3000","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"Escend Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Escend Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Escend Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Auron Therapeutics","sponsor":"DCVC Bio","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Series B Financing","leadProduct":"AUTX-703","moa":"KAT2A\/B","graph1":"Oncology","graph2":"IND Enabling","graph3":"Auron Therapeutics","amount2":0.029999999999999999,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0.029999999999999999,"dosageForm":"Oral","sponsorNew":"Auron Therapeutics \/ DCVC Bio","highestDevelopmentStatusID":"5","companyTruncated":"Auron Therapeutics \/ DCVC Bio"},{"orgOrder":0,"company":"CERo Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"CER-1236","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"CERo Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"CERo Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"CERo Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"CytoImmune Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"CYTO NK-201","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"CytoImmune Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"CytoImmune Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"CytoImmune Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"GT Biopharma","sponsor":"Fate Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"GTB-3650","moa":"||CD33","graph1":"Oncology","graph2":"IND Enabling","graph3":"GT Biopharma","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"GT Biopharma \/ Fate Therapeutics","highestDevelopmentStatusID":"5","companyTruncated":"GT Biopharma \/ Fate Therapeutics"},{"orgOrder":0,"company":"GT Biopharma","sponsor":"Cytovance Biologics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Agreement","leadProduct":"GTB-3650","moa":"CD33","graph1":"Oncology","graph2":"IND Enabling","graph3":"GT Biopharma","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"GT Biopharma \/ Cytovance Biologics","highestDevelopmentStatusID":"5","companyTruncated":"GT Biopharma \/ Cytovance Biologics"},{"orgOrder":0,"company":"Hemogenyx Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"HEMO-CAR-T","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"Hemogenyx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hemogenyx Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Hemogenyx Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Hemogenyx Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"HEMO-CAR-T","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"Hemogenyx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hemogenyx Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Hemogenyx Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Hemogenyx Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"HEMO-CAR-T","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"Hemogenyx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hemogenyx Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Hemogenyx Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Schrodinger","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"SGR-2921","moa":"||CDC7","graph1":"Oncology","graph2":"IND Enabling","graph3":"Schrodinger","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Schrodinger \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Schrodinger \/ Inapplicable"},{"orgOrder":0,"company":"Schrodinger","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"SGR-2921","moa":"||CDC7","graph1":"Oncology","graph2":"IND Enabling","graph3":"Schrodinger","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Schrodinger \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Schrodinger \/ Inapplicable"},{"orgOrder":0,"company":"Miltenyi Biotec","sponsor":"Cell BioEngines","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"GERMANY","productType":"Cell and Gene therapy","year":"2023","type":"Agreement","leadProduct":"CBE-101","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"Miltenyi Biotec","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Miltenyi Biotec \/ Cell BioEngines","highestDevelopmentStatusID":"5","companyTruncated":"Miltenyi Biotec \/ Cell BioEngines"},{"orgOrder":0,"company":"Acuitas","sponsor":"Myeloid Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CANADA","productType":"Microorganism","year":"2022","type":"Agreement","leadProduct":"MT-301","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"Acuitas","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Acuitas \/ Myeloid Therapeutics","highestDevelopmentStatusID":"5","companyTruncated":"Acuitas \/ Myeloid Therapeutics"},{"orgOrder":0,"company":"BioCity Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Large Molecule","year":"2024","type":"Inapplicable","leadProduct":"BC2027","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"BioCity Biopharma","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"BioCity Biopharma \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"BioCity Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"Alpha Tau Medical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Radium-224","moa":"Alpha-radiation","graph1":"Oncology","graph2":"IND Enabling","graph3":"Alpha Tau Medical","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Alpha Tau Medical \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Alpha Tau Medical \/ Inapplicable"},{"orgOrder":0,"company":"Aptamer Group","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Other Large Molecule","year":"2024","type":"Inapplicable","leadProduct":"AST-201","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"Aptamer Group","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Aptamer Group \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Aptamer Group \/ Inapplicable"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Surface Oncology","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Collaboration","leadProduct":"Casdozokitug","moa":"||IL-27 receptor","graph1":"Oncology","graph2":"IND Enabling","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Merck & Co \/ Surface Oncology","highestDevelopmentStatusID":"5","companyTruncated":"Merck & Co \/ Surface Oncology"},{"orgOrder":0,"company":"BioSyngen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SINGAPORE","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"BRL03","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"BioSyngen","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"BioSyngen \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"BioSyngen \/ Inapplicable"},{"orgOrder":0,"company":"Akamis Bio","sponsor":"Bluebird Bio","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"NG-347","moa":"||EGFR","graph1":"Oncology","graph2":"IND Enabling","graph3":"Akamis Bio","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Akamis Bio \/ Bluebird Bio","highestDevelopmentStatusID":"5","companyTruncated":"Akamis Bio \/ Bluebird Bio"},{"orgOrder":0,"company":"CDR Life","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"CDR404","moa":"Cytotoxic T-cell","graph1":"Oncology","graph2":"IND Enabling","graph3":"CDR Life","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"CDR Life \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"CDR Life \/ Inapplicable"},{"orgOrder":0,"company":"CDR Life","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"CDR404","moa":"Cytotoxic T-cell","graph1":"Oncology","graph2":"IND Enabling","graph3":"CDR Life","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"CDR Life \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"CDR Life \/ Inapplicable"},{"orgOrder":0,"company":"CDR Life","sponsor":"Jeito Capital","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Antibody","year":"2022","type":"Series A Financing","leadProduct":"CDR404","moa":"Cytotoxic T-cell","graph1":"Oncology","graph2":"IND Enabling","graph3":"CDR Life","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"CDR Life \/ Jeito Capital","highestDevelopmentStatusID":"5","companyTruncated":"CDR Life \/ Jeito Capital"},{"orgOrder":0,"company":"Salarius Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Deuterium Stabilized(S)-Avadomide","moa":"Cereblon","graph1":"Oncology","graph2":"IND Enabling","graph3":"Salarius Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Salarius Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Salarius Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Antengene","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Onatasertib","moa":"||TORC1\/TORC2","graph1":"Oncology","graph2":"IND Enabling","graph3":"Antengene","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Antengene \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Antengene \/ Inapplicable"},{"orgOrder":0,"company":"Duet BioTherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Oligonucleotide","year":"2022","type":"Inapplicable","leadProduct":"DUET-01","moa":"STAT3","graph1":"Oncology","graph2":"IND Enabling","graph3":"Duet BioTherapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Duet BioTherapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Duet BioTherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Estrella Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"EB103","moa":"CD19","graph1":"Oncology","graph2":"IND Enabling","graph3":"Estrella Biopharma","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Estrella Biopharma \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Estrella Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"LTZ Therapeutics","sponsor":"Lapam Capital","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Series A Financing","leadProduct":"LTZ-301","moa":"CD79b\/B-cell","graph1":"Oncology","graph2":"IND Enabling","graph3":"LTZ Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"LTZ Therapeutics \/ Lapam Capital","highestDevelopmentStatusID":"5","companyTruncated":"LTZ Therapeutics \/ Lapam Capital"},{"orgOrder":0,"company":"Nkarta Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"NKX019","moa":"CD19","graph1":"Oncology","graph2":"IND Enabling","graph3":"Nkarta Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Nkarta Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Nkarta Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Oncternal Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"ONCT-808","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"Oncternal Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Oncternal Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Oncternal Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Schrodinger","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"SGR-1505","moa":"MALT1","graph1":"Oncology","graph2":"IND Enabling","graph3":"Schrodinger","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Schrodinger \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Schrodinger \/ Inapplicable"},{"orgOrder":0,"company":"Scopus Biopharma","sponsor":"The Benchmark Company","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Public Offering","leadProduct":"CO-sTiRNA","moa":"||STAT3","graph1":"Oncology","graph2":"IND Enabling","graph3":"Scopus Biopharma","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Scopus Biopharma \/ The Benchmark Company","highestDevelopmentStatusID":"5","companyTruncated":"Scopus Biopharma \/ The Benchmark Company"},{"orgOrder":0,"company":"Dialectic Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"DT2216","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"Dialectic Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dialectic Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Dialectic Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Gamida Cell","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"Nam-Expanded Allogeneic NK Cell","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"Gamida Cell","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Gamida Cell \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Gamida Cell \/ Inapplicable"},{"orgOrder":0,"company":"Bantam Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"BTM-3566","moa":"HRI Kinase","graph1":"Oncology","graph2":"IND Enabling","graph3":"Bantam Pharmaceutical","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Bantam Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Bantam Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Bantam Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"BTM-3566","moa":"HRI Kinase","graph1":"Oncology","graph2":"IND Enabling","graph3":"Bantam Pharmaceutical","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Bantam Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Bantam Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Aleta Biotherapeutics","sponsor":"Cancer Research","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Collaboration","leadProduct":"ALETA-001","moa":"CD20","graph1":"Oncology","graph2":"IND Enabling","graph3":"Aleta Biotherapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Aleta Biotherapeutics \/ Cancer Research","highestDevelopmentStatusID":"5","companyTruncated":"Aleta Biotherapeutics \/ Cancer Research"},{"orgOrder":0,"company":"Lantern Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"LP-284","moa":"DNA","graph1":"Oncology","graph2":"IND Enabling","graph3":"Lantern Pharma","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Lantern Pharma \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Lantern Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Lantern Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"LP-284","moa":"DNA","graph1":"Oncology","graph2":"IND Enabling","graph3":"Lantern Pharma","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Lantern Pharma \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Lantern Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Lantern Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"LP-284","moa":"DNA","graph1":"Oncology","graph2":"IND Enabling","graph3":"Lantern Pharma","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Lantern Pharma \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Lantern Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Lantern Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"LP-284","moa":"DNA","graph1":"Oncology","graph2":"IND Enabling","graph3":"Lantern Pharma","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Lantern Pharma \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Lantern Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Chordia Therapeutics","sponsor":"Ono Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"JAPAN","productType":"Other Small Molecule","year":"2020","type":"Collaboration","leadProduct":"CTX-177","moa":"MALT1","graph1":"Oncology","graph2":"IND Enabling","graph3":"Chordia Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Chordia Therapeutics \/ Ono Pharmaceutical","highestDevelopmentStatusID":"5","companyTruncated":"Chordia Therapeutics \/ Ono Pharmaceutical"},{"orgOrder":0,"company":"Salarius Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Deuterium Stabilized(S)-Avadomide","moa":"Cereblon","graph1":"Oncology","graph2":"IND Enabling","graph3":"Salarius Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Salarius Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Salarius Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Salarius Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Deuterium Stabilized(S)-Avadomide","moa":"Cereblon","graph1":"Oncology","graph2":"IND Enabling","graph3":"Salarius Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Salarius Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Salarius Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"IASO Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"CT120","moa":"CD19\/22","graph1":"Oncology","graph2":"IND Enabling","graph3":"IASO Bio","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Inhalation","sponsorNew":"IASO Bio \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"IASO Bio \/ Inapplicable"},{"orgOrder":0,"company":"IASO Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"CT120","moa":"CD19\/22","graph1":"Oncology","graph2":"IND Enabling","graph3":"IASO Bio","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Inhalation","sponsorNew":"IASO Bio \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"IASO Bio \/ Inapplicable"},{"orgOrder":0,"company":"IASO Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"CT120","moa":"CD19\/22","graph1":"Oncology","graph2":"IND Enabling","graph3":"IASO Bio","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Inhalation","sponsorNew":"IASO Bio \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"IASO Bio \/ Inapplicable"},{"orgOrder":0,"company":"LTZ Therapeutics","sponsor":"Qiming Venture Partners","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Financing","leadProduct":"LTZ-301","moa":"CD79b\/B-cell","graph1":"Oncology","graph2":"IND Enabling","graph3":"LTZ Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"LTZ Therapeutics \/ Qiming Venture Partners","highestDevelopmentStatusID":"5","companyTruncated":"LTZ Therapeutics \/ Qiming Venture Partners"},{"orgOrder":0,"company":"Cellectis","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"UCART20x22","moa":"CD20\/22","graph1":"Oncology","graph2":"IND Enabling","graph3":"Cellectis","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Cellectis \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Cellectis \/ Inapplicable"},{"orgOrder":0,"company":"Cellectis","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"UCART20x22","moa":"CD20\/22","graph1":"Oncology","graph2":"IND Enabling","graph3":"Cellectis","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Cellectis \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Cellectis \/ Inapplicable"},{"orgOrder":0,"company":"Aurigene","sponsor":"Exelixis","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"INDIA","productType":"Other Small Molecule","year":"2021","type":"Licensing Agreement","leadProduct":"XL114","moa":"BTK","graph1":"Oncology","graph2":"IND Enabling","graph3":"Aurigene","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Aurigene \/ Exelixis","highestDevelopmentStatusID":"5","companyTruncated":"Aurigene \/ Exelixis"},{"orgOrder":0,"company":"BITT","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Large Molecule","year":"2023","type":"Inapplicable","leadProduct":"BITT-2101","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"BITT","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"BITT \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"BITT \/ Inapplicable"},{"orgOrder":0,"company":"Defence Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"AccuTOX","moa":"||Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"Defence Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Defence Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Defence Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Hoth Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"HT-KIT","moa":"c-KIT receptor","graph1":"Oncology","graph2":"IND Enabling","graph3":"Hoth Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hoth Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Hoth Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Hoth Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"HT-KIT","moa":"c-KIT receptor","graph1":"Oncology","graph2":"IND Enabling","graph3":"Hoth Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hoth Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Hoth Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Hoth Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"HT-KIT","moa":"c-KIT receptor","graph1":"Oncology","graph2":"IND Enabling","graph3":"Hoth Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hoth Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Hoth Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Iovance Biotherapeutics","sponsor":"Cellectis","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"IOV-4001","moa":"TIL","graph1":"Oncology","graph2":"IND Enabling","graph3":"Iovance Biotherapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Iovance Biotherapeutics \/ Cellectis","highestDevelopmentStatusID":"5","companyTruncated":"Iovance Biotherapeutics \/ Cellectis"},{"orgOrder":0,"company":"Immuneering Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"IMM-1-104","moa":"MEK receptor","graph1":"Oncology","graph2":"IND Enabling","graph3":"Immuneering Corporation","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Immuneering Corporation \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Immuneering Corporation \/ Inapplicable"},{"orgOrder":0,"company":"TScan Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"TSC-203-A0201","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"TScan Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"TScan Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"TScan Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"OneThree Biotech","sponsor":"Jubilant Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Collaboration","leadProduct":"JBI-802","moa":"LSD1\/HDAC6","graph1":"Oncology","graph2":"IND Enabling","graph3":"OneThree Biotech","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"OneThree Biotech \/ Jubilant Therapeutics","highestDevelopmentStatusID":"5","companyTruncated":"OneThree Biotech \/ Jubilant Therapeutics"},{"orgOrder":0,"company":"Ikena Oncology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"IK-930","moa":"TEAD","graph1":"Oncology","graph2":"IND Enabling","graph3":"Ikena Oncology","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Ikena Oncology \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Ikena Oncology \/ Inapplicable"},{"orgOrder":0,"company":"Ikena Oncology","sponsor":"Jefferies","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Public Offering","leadProduct":"IK-930","moa":"TEAD","graph1":"Oncology","graph2":"IND Enabling","graph3":"Ikena Oncology","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Ikena Oncology \/ Jefferies","highestDevelopmentStatusID":"5","companyTruncated":"Ikena Oncology \/ Jefferies"},{"orgOrder":0,"company":"Atara Biotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"ATA3271","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"Atara Biotherapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Atara Biotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Atara Biotherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Harbour BioMed","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Large Molecule","year":"2023","type":"Inapplicable","leadProduct":"HBM9033","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"Harbour BioMed","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Harbour BioMed \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Harbour BioMed \/ Inapplicable"},{"orgOrder":0,"company":"Vertical bio","sponsor":"Pierre Fabre","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Other Large Molecule","year":"2023","type":"Acquisition","leadProduct":"PFL-002","moa":"c-Met receptor","graph1":"Oncology","graph2":"IND Enabling","graph3":"Vertical bio","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Vertical bio \/ Pierre Fabre","highestDevelopmentStatusID":"5","companyTruncated":"Vertical bio \/ Pierre Fabre"},{"orgOrder":0,"company":"Zymeworks","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Other Large Molecule","year":"2024","type":"Inapplicable","leadProduct":"ZW171","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"Zymeworks","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Zymeworks \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Zymeworks \/ Inapplicable"},{"orgOrder":0,"company":"Ideaya Biosciences","sponsor":"Amgen Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"AMG 193","moa":"||MAT2A","graph1":"Oncology","graph2":"IND Enabling","graph3":"Ideaya Biosciences","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Ideaya Biosciences \/ Amgen Inc","highestDevelopmentStatusID":"5","companyTruncated":"Ideaya Biosciences \/ Amgen Inc"},{"orgOrder":0,"company":"Ideaya Biosciences","sponsor":"Gilead Sciences","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Collaboration","leadProduct":"IDE397","moa":"||MAT2A","graph1":"Oncology","graph2":"IND Enabling","graph3":"Ideaya Biosciences","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Ideaya Biosciences \/ Gilead Sciences","highestDevelopmentStatusID":"5","companyTruncated":"Ideaya Biosciences \/ Gilead Sciences"},{"orgOrder":0,"company":"OncoMyx Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"OM1","moa":"IL-15 receptor","graph1":"Oncology","graph2":"IND Enabling","graph3":"OncoMyx Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"OncoMyx Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"OncoMyx Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"ALX Oncology","sponsor":"Sanofi","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2023","type":"Collaboration","leadProduct":"Evorpacept","moa":"||CD47","graph1":"Oncology","graph2":"IND Enabling","graph3":"ALX Oncology","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"ALX Oncology \/ Sanofi","highestDevelopmentStatusID":"5","companyTruncated":"ALX Oncology \/ Sanofi"},{"orgOrder":0,"company":"CASI Pharmaceuticals","sponsor":"Cleave Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"CB-5339 Tosylate","moa":"VCP\/p97","graph1":"Oncology","graph2":"IND Enabling","graph3":"CASI Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"CASI Pharmaceuticals \/ Cleave Therapeutics","highestDevelopmentStatusID":"5","companyTruncated":"CASI Pharmaceuticals \/ Cleave Therapeutics"},{"orgOrder":0,"company":"Kronos Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"KB-9558","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"Kronos Bio","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Kronos Bio \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Kronos Bio \/ Inapplicable"},{"orgOrder":0,"company":"Replay Bio","sponsor":"The University of Texas MD Anderson Cancer Center","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"Replay Bio","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Replay Bio \/ The University of Texas MD Anderson Cancer Center","highestDevelopmentStatusID":"5","companyTruncated":"Replay Bio \/ The University of Texas MD Anderson Cancer Center"},{"orgOrder":0,"company":"Virtuoso Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Undisclosed","moa":"CD-38\/ICAM-1","graph1":"Oncology","graph2":"IND Enabling","graph3":"Virtuoso Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Virtuoso Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Virtuoso Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Kleo Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"KP1237","moa":"||CD-38","graph1":"Oncology","graph2":"IND Enabling","graph3":"Kleo Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Kleo Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Kleo Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Kleo Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"KP1237","moa":"||CD-38","graph1":"Oncology","graph2":"IND Enabling","graph3":"Kleo Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Kleo Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Kleo Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Kleo Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"KP1237","moa":"||CD-38","graph1":"Oncology","graph2":"IND Enabling","graph3":"Kleo Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Kleo Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Kleo Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"InnoCare Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"ICP-490","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"InnoCare Pharma","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"InnoCare Pharma \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"InnoCare Pharma \/ Inapplicable"},{"orgOrder":0,"company":"ONK Therapeutics","sponsor":"Acorn Bioventures","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"IRELAND","productType":"Cell and Gene therapy","year":"2022","type":"Series A Financing","leadProduct":"ONKT102","moa":"CD-38","graph1":"Oncology","graph2":"IND Enabling","graph3":"ONK Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ONK Therapeutics \/ Acorn Bioventures","highestDevelopmentStatusID":"5","companyTruncated":"ONK Therapeutics \/ Acorn Bioventures"},{"orgOrder":0,"company":"ONK Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"IRELAND","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"ONKT102","moa":"CD-38","graph1":"Oncology","graph2":"IND Enabling","graph3":"ONK Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ONK Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"ONK Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"ONK Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"IRELAND","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"ONKT102","moa":"CD-38","graph1":"Oncology","graph2":"IND Enabling","graph3":"ONK Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ONK Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"ONK Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Oncopeptides","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Peptide","year":"2020","type":"Inapplicable","leadProduct":"OPD5","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"Oncopeptides","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Oncopeptides \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Oncopeptides \/ Inapplicable"},{"orgOrder":0,"company":"Mustang Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"MB-104","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"Mustang Bio","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Mustang Bio \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Mustang Bio \/ Inapplicable"},{"orgOrder":0,"company":"OnKure Therapeutics","sponsor":"Surveyor Capital","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Series C Financing","leadProduct":"OKI-219","moa":"PI3K-alpha-H1047R","graph1":"Oncology","graph2":"IND Enabling","graph3":"OnKure Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"OnKure Therapeutics \/ Surveyor Capital","highestDevelopmentStatusID":"5","companyTruncated":"OnKure Therapeutics \/ Surveyor Capital"},{"orgOrder":0,"company":"INmune Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"INKmune","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"INmune Bio","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"INmune Bio \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"INmune Bio \/ Inapplicable"},{"orgOrder":0,"company":"INmune Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"INKmune","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"INmune Bio","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"INmune Bio \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"INmune Bio \/ Inapplicable"},{"orgOrder":0,"company":"Aprea Therapeutics","sponsor":"Karolinska Development AB","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"APR-548","moa":"p53","graph1":"Oncology","graph2":"IND Enabling","graph3":"Aprea Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Aprea Therapeutics \/ Karolinska Development AB","highestDevelopmentStatusID":"5","companyTruncated":"Aprea Therapeutics \/ Karolinska Development AB"},{"orgOrder":0,"company":"Molecular Targeting Technologies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"177-Lu DOTA-EB-TATE","moa":"SST2 receptor","graph1":"Oncology","graph2":"IND Enabling","graph3":"Molecular Targeting Technologies","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Molecular Targeting Technologies \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Molecular Targeting Technologies \/ Inapplicable"},{"orgOrder":0,"company":"Tagworks Pharmaceuticals","sponsor":"Ysios Capital","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"NETHERLANDS","productType":"Other Large Molecule","year":"2023","type":"Series A Financing","leadProduct":"TGW101","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"Tagworks Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Tagworks Pharmaceuticals \/ Ysios Capital","highestDevelopmentStatusID":"5","companyTruncated":"Tagworks Pharmaceuticals \/ Ysios Capital"},{"orgOrder":0,"company":"Tagworks Pharmaceuticals","sponsor":"Ysios Capital","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"NETHERLANDS","productType":"Other Large Molecule","year":"2023","type":"Series A Financing","leadProduct":"TGW101","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"Tagworks Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Tagworks Pharmaceuticals \/ Ysios Capital","highestDevelopmentStatusID":"5","companyTruncated":"Tagworks Pharmaceuticals \/ Ysios Capital"},{"orgOrder":0,"company":"Editas Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"EDIT-202","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"Editas Medicine","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intraperitoneal Injection","sponsorNew":"Editas Medicine \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Editas Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Editas Medicine","sponsor":"Shoreline Biosciences","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Acquisition","leadProduct":"EDIT-202","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"Editas Medicine","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intraperitoneal Injection","sponsorNew":"Editas Medicine \/ Shoreline Biosciences","highestDevelopmentStatusID":"5","companyTruncated":"Editas Medicine \/ Shoreline Biosciences"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Akamis Bio","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Collaboration","leadProduct":"NG-641","moa":"||AP\/CD3","graph1":"Oncology","graph2":"IND Enabling","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intrathecal Injection","sponsorNew":"Bristol Myers Squibb \/ Akamis Bio","highestDevelopmentStatusID":"5","companyTruncated":"Bristol Myers Squibb \/ Akamis Bio"},{"orgOrder":0,"company":"Merck Group","sponsor":"Immutep","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"GERMANY","productType":"Protein","year":"2021","type":"Collaboration","leadProduct":"Eftilagimod Alpha","moa":"||APC receptor","graph1":"Oncology","graph2":"IND Enabling","graph3":"Merck Group","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Infusion","sponsorNew":"Merck Group \/ Immutep","highestDevelopmentStatusID":"5","companyTruncated":"Merck Group \/ Immutep"},{"orgOrder":0,"company":"Mosaic ImmunoEngineering","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Microorganism","year":"2021","type":"Inapplicable","leadProduct":"MIE-101","moa":"Toll-like receptor","graph1":"Oncology","graph2":"IND Enabling","graph3":"Mosaic ImmunoEngineering","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Mosaic ImmunoEngineering \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Mosaic ImmunoEngineering \/ Inapplicable"},{"orgOrder":0,"company":"Mosaic ImmunoEngineering","sponsor":"University of California San Diego","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Microorganism","year":"2021","type":"Licensing Agreement","leadProduct":"MIE-101","moa":"Toll-like receptor","graph1":"Oncology","graph2":"IND Enabling","graph3":"Mosaic ImmunoEngineering","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Mosaic ImmunoEngineering \/ University of California San Diego","highestDevelopmentStatusID":"5","companyTruncated":"Mosaic ImmunoEngineering \/ University of California San Diego"},{"orgOrder":0,"company":"Presage Biosciences","sponsor":"Labcorp","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"Presage Biosciences","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Presage Biosciences \/ Labcorp","highestDevelopmentStatusID":"5","companyTruncated":"Presage Biosciences \/ Labcorp"},{"orgOrder":0,"company":"Presage Biosciences","sponsor":"Pure Biologics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Large Molecule","year":"2024","type":"Inapplicable","leadProduct":"PBA-0405","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"Presage Biosciences","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Presage Biosciences \/ Pure Biologics","highestDevelopmentStatusID":"5","companyTruncated":"Presage Biosciences \/ Pure Biologics"},{"orgOrder":0,"company":"ProBioGen","sponsor":"Asher Biotherapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"GERMANY","productType":"Protein","year":"2021","type":"Collaboration","leadProduct":"Etakafusp Alpha","moa":"IL-2 receptor","graph1":"Oncology","graph2":"IND Enabling","graph3":"ProBioGen","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"ProBioGen \/ Asher Biotherapeutics","highestDevelopmentStatusID":"5","companyTruncated":"ProBioGen \/ Asher Biotherapeutics"},{"orgOrder":0,"company":"InxMed","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody-drug Conjugate","year":"2023","type":"Inapplicable","leadProduct":"OMTX705","moa":"FAP-alpha","graph1":"Oncology","graph2":"IND Enabling","graph3":"InxMed","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"InxMed \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"InxMed \/ Inapplicable"},{"orgOrder":0,"company":"Ascendis Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"DENMARK","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"TransCon IL-2","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"Ascendis Pharma","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Ascendis Pharma \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Ascendis Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Ascendis Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"DENMARK","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"TransCon IL-2","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"Ascendis Pharma","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Ascendis Pharma \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Ascendis Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Lonza Group","sponsor":"Triumvira Immunologics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Cell and Gene therapy","year":"2020","type":"Collaboration","leadProduct":"TAC01-HER2","moa":"HER2","graph1":"Oncology","graph2":"IND Enabling","graph3":"Lonza Group","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Lonza Group \/ Triumvira Immunologics","highestDevelopmentStatusID":"5","companyTruncated":"Lonza Group \/ Triumvira Immunologics"},{"orgOrder":0,"company":"Agenus","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"AgenT-797","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"Agenus","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Agenus \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Agenus \/ Inapplicable"},{"orgOrder":0,"company":"Y-mAbs Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"GD2-SADA","moa":"GD2","graph1":"Oncology","graph2":"IND Enabling","graph3":"Y-mAbs Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Y-mAbs Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Y-mAbs Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Likang Life Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"LK101","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"Likang Life Sciences","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Likang Life Sciences \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Likang Life Sciences \/ Inapplicable"},{"orgOrder":0,"company":"HEPHAISTOS-Pharma","sponsor":"Xista Science Ventures","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"FRANCE","productType":"Undisclosed","year":"2024","type":"Financing","leadProduct":"Onco-Boost","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"HEPHAISTOS-Pharma","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"HEPHAISTOS-Pharma \/ Xista Science Ventures","highestDevelopmentStatusID":"5","companyTruncated":"HEPHAISTOS-Pharma \/ Xista Science Ventures"},{"orgOrder":0,"company":"Avidea Technologies","sponsor":"Barinthus Biotherapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Acquisition","leadProduct":"SNAPvax CV","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"Avidea Technologies","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Avidea Technologies \/ Barinthus Biotherapeutics","highestDevelopmentStatusID":"5","companyTruncated":"Avidea Technologies \/ Barinthus Biotherapeutics"},{"orgOrder":0,"company":"Trueline Therapeutics","sponsor":"Broad Institute","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"TTX-810","moa":"MCL1","graph1":"Oncology","graph2":"IND Enabling","graph3":"Trueline Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Trueline Therapeutics \/ Broad Institute","highestDevelopmentStatusID":"5","companyTruncated":"Trueline Therapeutics \/ Broad Institute"},{"orgOrder":0,"company":"Celcuity","sponsor":"Pfizer Inc","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Collaboration","leadProduct":"Gedatolisib","moa":"||PI3K\/mTOR","graph1":"Oncology","graph2":"IND Enabling","graph3":"Celcuity","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Celcuity \/ Pfizer Inc","highestDevelopmentStatusID":"5","companyTruncated":"Celcuity \/ Pfizer Inc"},{"orgOrder":0,"company":"KaliVir Immunotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"ASP1012","moa":"Leptin-IL2 fusion protein expression","graph1":"Oncology","graph2":"IND Enabling","graph3":"KaliVir Immunotherapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"KaliVir Immunotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"KaliVir Immunotherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"iOmx Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"OMX-0407","moa":"SIK3","graph1":"Oncology","graph2":"IND Enabling","graph3":"iOmx Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"iOmx Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"iOmx Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"280Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"TEB-17231","moa":"KRAS","graph1":"Oncology","graph2":"IND Enabling","graph3":"280Bio","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"280Bio \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"280Bio \/ Inapplicable"},{"orgOrder":0,"company":"Biomea Fusion","sponsor":"Cormorant Asset Management","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Series A Financing","leadProduct":"BMF-219","moa":"Menin","graph1":"Oncology","graph2":"IND Enabling","graph3":"Biomea Fusion","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Biomea Fusion \/ Cormorant Asset Management","highestDevelopmentStatusID":"5","companyTruncated":"Biomea Fusion \/ Cormorant Asset Management"},{"orgOrder":0,"company":"Calithera Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"CB-668","moa":"IL-4-I-1","graph1":"Oncology","graph2":"IND Enabling","graph3":"Calithera Biosciences","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Calithera Biosciences \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Calithera Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"City of Hope","sponsor":"Scopus Biopharma","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"STAT3","graph1":"Oncology","graph2":"IND Enabling","graph3":"City of Hope","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"City of Hope \/ Scopus Biopharma","highestDevelopmentStatusID":"5","companyTruncated":"City of Hope \/ Scopus Biopharma"},{"orgOrder":0,"company":"Cullgen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"CG001419","moa":"TRK receptor","graph1":"Oncology","graph2":"IND Enabling","graph3":"Cullgen","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Cullgen \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Cullgen \/ Inapplicable"},{"orgOrder":0,"company":"Erasca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"ERAS-3490","moa":"KRAS G12C","graph1":"Oncology","graph2":"IND Enabling","graph3":"Erasca","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Erasca \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Erasca \/ Inapplicable"},{"orgOrder":0,"company":"Focus Fund GP","sponsor":"The University of Texas MD Anderson Cancer Center","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Partnership","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"Focus Fund GP","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Focus Fund GP \/ The University of Texas MD Anderson Cancer Center","highestDevelopmentStatusID":"5","companyTruncated":"Focus Fund GP \/ The University of Texas MD Anderson Cancer Center"},{"orgOrder":0,"company":"Frontier Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"FMC-376","moa":"GTP-bound","graph1":"Oncology","graph2":"IND Enabling","graph3":"Frontier Medicine","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Frontier Medicine \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Frontier Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Mirati Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"MRTX1133","moa":"KRASG12D selective","graph1":"Oncology","graph2":"IND Enabling","graph3":"Mirati Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Mirati Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Mirati Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Pliant Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"PLN-101095","moa":"Alpha-5-beta-1\/Alpha-5-beta-8","graph1":"Oncology","graph2":"IND Enabling","graph3":"Pliant Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Pliant Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Pliant Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Sutro Biopharma","sponsor":"Merck & Co","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"Sutro Biopharma","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Sutro Biopharma \/ Merck & Co","highestDevelopmentStatusID":"5","companyTruncated":"Sutro Biopharma \/ Merck & Co"},{"orgOrder":0,"company":"Cullgen","sponsor":"3E Bioventures","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Series B Financing","leadProduct":"CG001419","moa":"TRK receptor","graph1":"Oncology","graph2":"IND Enabling","graph3":"Cullgen","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Cullgen \/ 3E Bioventures","highestDevelopmentStatusID":"5","companyTruncated":"Cullgen \/ 3E Bioventures"},{"orgOrder":0,"company":"Scripps Research","sponsor":"AbbVie Inc","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"Scripps Research","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Scripps Research \/ AbbVie Inc","highestDevelopmentStatusID":"5","companyTruncated":"Scripps Research \/ AbbVie Inc"},{"orgOrder":0,"company":"Scripps Research","sponsor":"AbbVie Inc","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Expanded Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"Scripps Research","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Scripps Research \/ AbbVie Inc","highestDevelopmentStatusID":"5","companyTruncated":"Scripps Research \/ AbbVie Inc"},{"orgOrder":0,"company":"Merck Group","sponsor":"Day One Biopharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"GERMANY","productType":"Other Small Molecule","year":"2021","type":"Licensing Agreement","leadProduct":"Pimasertib","moa":"||MEK1\/2 receptor","graph1":"Oncology","graph2":"IND Enabling","graph3":"Merck Group","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Merck Group \/ Day One Biopharmaceuticals","highestDevelopmentStatusID":"5","companyTruncated":"Merck Group \/ Day One Biopharmaceuticals"},{"orgOrder":0,"company":"Sairiyo Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Cepharanthine DiHCl","moa":"KEAP1-Nrf2","graph1":"Oncology","graph2":"IND Enabling","graph3":"Sairiyo Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Sairiyo Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Sairiyo Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Sairiyo Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Cepharanthine DiHCl","moa":"KEAP1-Nrf2","graph1":"Oncology","graph2":"IND Enabling","graph3":"Sairiyo Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Sairiyo Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Sairiyo Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Ascletis Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"ASC60","moa":"Fatty acid synthase","graph1":"Oncology","graph2":"IND Enabling","graph3":"Ascletis Pharma","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Ascletis Pharma \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Ascletis Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Full-Life Technologies","sponsor":"Sequoia Capital","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2022","type":"Series A Financing","leadProduct":"Undisclosed","moa":"Fibroblast protein","graph1":"Oncology","graph2":"IND Enabling","graph3":"Full-Life Technologies","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Full-Life Technologies \/ Sequoia Capital","highestDevelopmentStatusID":"5","companyTruncated":"Full-Life Technologies \/ Sequoia Capital"},{"orgOrder":0,"company":"HJB","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"Undisclosed","moa":"CLDN18.2","graph1":"Oncology","graph2":"IND Enabling","graph3":"HJB","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"HJB \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"HJB \/ Inapplicable"},{"orgOrder":0,"company":"VelaVigo","sponsor":"Avenzo Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2024","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"Nectin4\/TROP2","graph1":"Oncology","graph2":"IND Enabling","graph3":"VelaVigo","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"VelaVigo \/ Avenzo Therapeutics","highestDevelopmentStatusID":"5","companyTruncated":"VelaVigo \/ Avenzo Therapeutics"},{"orgOrder":0,"company":"Full-Life Technologies","sponsor":"Focus-X Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2022","type":"Acquisition","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"Full-Life Technologies","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Full-Life Technologies \/ Focus-X Therapeutics","highestDevelopmentStatusID":"5","companyTruncated":"Full-Life Technologies \/ Focus-X Therapeutics"},{"orgOrder":0,"company":"Insilico Medicine","sponsor":"Exelixis","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"HONG KONG","productType":"Other Small Molecule","year":"2023","type":"Licensing Agreement","leadProduct":"ISM3091","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"Insilico Medicine","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Insilico Medicine \/ Exelixis","highestDevelopmentStatusID":"5","companyTruncated":"Insilico Medicine \/ Exelixis"},{"orgOrder":0,"company":"Genenta Science","sponsor":"Ospedale San Raffaele","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"ITALY","productType":"Undisclosed","year":"2023","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"Genenta Science","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Genenta Science \/ Ospedale San Raffaele","highestDevelopmentStatusID":"5","companyTruncated":"Genenta Science \/ Ospedale San Raffaele"},{"orgOrder":0,"company":"Bright Peak Therapeutics","sponsor":"Ridgeline Therapeutics Discovery","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Undisclosed","year":"2020","type":"Series A Financing","leadProduct":"Undisclosed","moa":"CD25","graph1":"Oncology","graph2":"IND Enabling","graph3":"Bright Peak Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Bright Peak Therapeutics \/ Ridgeline Therapeutics Discovery","highestDevelopmentStatusID":"5","companyTruncated":"Bright Peak Therapeutics \/ Ridgeline Therapeutics Discovery"},{"orgOrder":0,"company":"Bright Peak Therapeutics","sponsor":"Ajinomoto Bio-Pharma","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Undisclosed","year":"2021","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"Bright Peak Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Bright Peak Therapeutics \/ Ajinomoto Bio-Pharma","highestDevelopmentStatusID":"5","companyTruncated":"Bright Peak Therapeutics \/ Ajinomoto Bio-Pharma"},{"orgOrder":0,"company":"Glenmark Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"INDIA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"GRC 54276","moa":"HPK1","graph1":"Oncology","graph2":"IND Enabling","graph3":"Glenmark Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Glenmark Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Glenmark Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Editas Medicine","sponsor":"Immatics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"Editas Medicine","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Editas Medicine \/ Immatics","highestDevelopmentStatusID":"5","companyTruncated":"Editas Medicine \/ Immatics"},{"orgOrder":0,"company":"Affini-T Therapeutics","sponsor":"Vida Ventures LLC","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Financing","leadProduct":"Undisclosed","moa":"KRAS G12V","graph1":"Oncology","graph2":"IND Enabling","graph3":"Affini-T Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Affini-T Therapeutics \/ Vida Ventures LLC","highestDevelopmentStatusID":"5","companyTruncated":"Affini-T Therapeutics \/ Vida Ventures LLC"},{"orgOrder":0,"company":"Editas Medicine","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"Editas Medicine","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Editas Medicine \/ Bristol Myers Squibb","highestDevelopmentStatusID":"5","companyTruncated":"Editas Medicine \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"Affini-T Therapeutics","sponsor":"ElevateBio","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Partnership","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"Affini-T Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Affini-T Therapeutics \/ ElevateBio","highestDevelopmentStatusID":"5","companyTruncated":"Affini-T Therapeutics \/ ElevateBio"},{"orgOrder":0,"company":"University of Michigan","sponsor":"Ascentage Pharma","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"MDM2 protein","graph1":"Oncology","graph2":"IND Enabling","graph3":"University of Michigan","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"University of Michigan \/ Ascentage Pharma","highestDevelopmentStatusID":"5","companyTruncated":"University of Michigan \/ Ascentage Pharma"},{"orgOrder":0,"company":"Jubilant Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"JBI-2174","moa":"PD-L1","graph1":"Oncology","graph2":"IND Enabling","graph3":"Jubilant Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Jubilant Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Jubilant Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Jubilant Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"JBI-778","moa":"PRMT5","graph1":"Oncology","graph2":"IND Enabling","graph3":"Jubilant Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Jubilant Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Jubilant Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Seed Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"ST-00937","moa":"RBM39","graph1":"Oncology","graph2":"IND Enabling","graph3":"Seed Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Seed Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Seed Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Tarus Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"TT-4","moa":"Adenosine A2B receptor","graph1":"Oncology","graph2":"IND Enabling","graph3":"Tarus Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Tarus Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Tarus Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Tarus Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"TT-4","moa":"Adenosine A2B receptor","graph1":"Oncology","graph2":"IND Enabling","graph3":"Tarus Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Tarus Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Tarus Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Abalos","sponsor":"Seventure Partners","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"GERMANY","productType":"Undisclosed","year":"2021","type":"Series A Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"Abalos","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Abalos \/ Seventure Partners","highestDevelopmentStatusID":"5","companyTruncated":"Abalos \/ Seventure Partners"},{"orgOrder":0,"company":"Tachyon Technologies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"TACH101","moa":"KDM4 histone demethylase","graph1":"Oncology","graph2":"IND Enabling","graph3":"Tachyon Technologies","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Tachyon Technologies \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Tachyon Technologies \/ Inapplicable"},{"orgOrder":0,"company":"Tachyon Technologies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"TACH101","moa":"KDM4 histone demethylase","graph1":"Oncology","graph2":"IND Enabling","graph3":"Tachyon Technologies","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Tachyon Technologies \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Tachyon Technologies \/ Inapplicable"},{"orgOrder":0,"company":"Adaptive Biotechnologies","sponsor":"Genentech","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"Adaptive Biotechnologies","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Adaptive Biotechnologies \/ Genentech","highestDevelopmentStatusID":"5","companyTruncated":"Adaptive Biotechnologies \/ Genentech"},{"orgOrder":0,"company":"ImmunOs Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"IOS-1002","moa":"LILRB1\/LILRB2\/KIR3DL1","graph1":"Oncology","graph2":"IND Enabling","graph3":"ImmunOs Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Inhalation","sponsorNew":"ImmunOs Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"ImmunOs Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"ImmunOs Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"IOS-1002","moa":"LILRB1\/LILRB2\/KIR3DL1","graph1":"Oncology","graph2":"IND Enabling","graph3":"ImmunOs Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Inhalation","sponsorNew":"ImmunOs Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"ImmunOs Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Shanghai Junshi Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"JS110","moa":"XPO1","graph1":"Oncology","graph2":"IND Enabling","graph3":"Shanghai Junshi Biosciences","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Shanghai Junshi Biosciences \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Shanghai Junshi Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"SunHo","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"IAP0971","moa":"PD-1","graph1":"Oncology","graph2":"IND Enabling","graph3":"SunHo","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"SunHo \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"SunHo \/ Inapplicable"},{"orgOrder":0,"company":"Krystal Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Large Molecule","year":"2023","type":"Inapplicable","leadProduct":"KB707","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"Krystal Biotech","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Krystal Biotech \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Krystal Biotech \/ Inapplicable"},{"orgOrder":0,"company":"iOmx Therapeutics","sponsor":"Athos Service","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"GERMANY","productType":"Other Small Molecule","year":"2021","type":"Series B Financing","leadProduct":"IMT-07","moa":"SIK3","graph1":"Oncology","graph2":"IND Enabling","graph3":"iOmx Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"iOmx Therapeutics \/ Athos Service","highestDevelopmentStatusID":"5","companyTruncated":"iOmx Therapeutics \/ Athos Service"},{"orgOrder":0,"company":"MorphoSys","sponsor":"I-Mab Biopharma","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"MOR210","moa":"||C5a receptor","graph1":"Oncology","graph2":"IND Enabling","graph3":"MorphoSys","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"MorphoSys \/ I-Mab Biopharma","highestDevelopmentStatusID":"5","companyTruncated":"MorphoSys \/ I-Mab Biopharma"},{"orgOrder":0,"company":"T-knife","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"TK-2504","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"T-knife","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"T-knife \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"T-knife \/ Inapplicable"},{"orgOrder":0,"company":"Amunix","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"AMX-818","moa":"Dysregulated protease","graph1":"Oncology","graph2":"IND Enabling","graph3":"Amunix","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Amunix \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Amunix \/ Inapplicable"},{"orgOrder":0,"company":"Amunix","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"AMX-818","moa":"Dysregulated protease","graph1":"Oncology","graph2":"IND Enabling","graph3":"Amunix","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Amunix \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Amunix \/ Inapplicable"},{"orgOrder":0,"company":"Amunix","sponsor":"Omega Funds","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Series A Financing","leadProduct":"AMX-818","moa":"Dysregulated protease","graph1":"Oncology","graph2":"IND Enabling","graph3":"Amunix","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Amunix \/ Omega Funds","highestDevelopmentStatusID":"5","companyTruncated":"Amunix \/ Omega Funds"},{"orgOrder":0,"company":"Asher Biotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"AB821","moa":"IL-21 receptor","graph1":"Oncology","graph2":"IND Enabling","graph3":"Asher Biotherapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Asher Biotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Asher Biotherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Atreca","sponsor":"Zymeworks","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2022","type":"Licensing Agreement","leadProduct":"ATRC-301","moa":"Ephrin type A2 receptor","graph1":"Oncology","graph2":"IND Enabling","graph3":"Atreca","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Atreca \/ Zymeworks","highestDevelopmentStatusID":"5","companyTruncated":"Atreca \/ Zymeworks"},{"orgOrder":0,"company":"aTyr Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"ATYR2810","moa":"NRP2 receptor","graph1":"Oncology","graph2":"IND Enabling","graph3":"aTyr Pharma","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"aTyr Pharma \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"aTyr Pharma \/ Inapplicable"},{"orgOrder":0,"company":"aTyr Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"ATYR2810","moa":"NRP2 receptor","graph1":"Oncology","graph2":"IND Enabling","graph3":"aTyr Pharma","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"aTyr Pharma \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"aTyr Pharma \/ Inapplicable"},{"orgOrder":0,"company":"aTyr Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"ATYR2810","moa":"NRP2 receptor","graph1":"Oncology","graph2":"IND Enabling","graph3":"aTyr Pharma","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"aTyr Pharma \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"aTyr Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Calidi Biotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"SNV1","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"Calidi Biotherapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Calidi Biotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Calidi Biotherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"FibroGen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Large Molecule","year":"2024","type":"Inapplicable","leadProduct":"FG-3165","moa":"Galectin-9","graph1":"Oncology","graph2":"IND Enabling","graph3":"FibroGen","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"FibroGen \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"FibroGen \/ Inapplicable"},{"orgOrder":0,"company":"Harpoon Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Peptide","year":"2020","type":"Inapplicable","leadProduct":"HPN601","moa":"EpCAM","graph1":"Oncology","graph2":"IND Enabling","graph3":"Harpoon Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Harpoon Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Harpoon Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Harpoon Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Peptide","year":"2020","type":"Inapplicable","leadProduct":"HPN601","moa":"EpCAM","graph1":"Oncology","graph2":"IND Enabling","graph3":"Harpoon Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Harpoon Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Harpoon Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"ImaginAb","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"IAB56","moa":"Alpha-V-beta-6 integrin","graph1":"Oncology","graph2":"IND Enabling","graph3":"ImaginAb","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ImaginAb \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"ImaginAb \/ Inapplicable"},{"orgOrder":0,"company":"Immune-Onc Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"IO-106","moa":"LAIR-1","graph1":"Oncology","graph2":"IND Enabling","graph3":"Immune-Onc Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Immune-Onc Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Immune-Onc Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Kinnate Biopharma","sponsor":"Tempus","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"KIN004","moa":"CDK12","graph1":"Oncology","graph2":"IND Enabling","graph3":"Kinnate Biopharma","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Kinnate Biopharma \/ Tempus","highestDevelopmentStatusID":"5","companyTruncated":"Kinnate Biopharma \/ Tempus"},{"orgOrder":0,"company":"Kivu Bioscience","sponsor":"Organovo Holdings","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Large Molecule","year":"2024","type":"Series A Financing","leadProduct":"KIVU-107","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"Kivu Bioscience","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Kivu Bioscience \/ Organovo Holdings","highestDevelopmentStatusID":"5","companyTruncated":"Kivu Bioscience \/ Organovo Holdings"},{"orgOrder":0,"company":"Kura Oncology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"KO-2806","moa":"Farnesyl transferase","graph1":"Oncology","graph2":"IND Enabling","graph3":"Kura Oncology","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Kura Oncology \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Kura Oncology \/ Inapplicable"},{"orgOrder":0,"company":"LadRx","sponsor":"XOMA","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Large Molecule","year":"2023","type":"Financing","leadProduct":"AE-Keto-Sulf07","moa":"Tubulin","graph1":"Oncology","graph2":"IND Enabling","graph3":"LadRx","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"LadRx \/ XOMA","highestDevelopmentStatusID":"5","companyTruncated":"LadRx \/ XOMA"},{"orgOrder":0,"company":"Metagenomi","sponsor":"Affini-T Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Partnership","leadProduct":"AFNT-111","moa":"KRAS G12V","graph1":"Oncology","graph2":"IND Enabling","graph3":"Metagenomi","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Metagenomi \/ Affini-T Therapeutics","highestDevelopmentStatusID":"5","companyTruncated":"Metagenomi \/ Affini-T Therapeutics"},{"orgOrder":0,"company":"Qualigen Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"QN-302","moa":"G4-quadruplex transcription","graph1":"Oncology","graph2":"IND Enabling","graph3":"Qualigen Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Qualigen Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Qualigen Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Qualigen Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"QN-302","moa":"G4-quadruplex transcription","graph1":"Oncology","graph2":"IND Enabling","graph3":"Qualigen Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Qualigen Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Qualigen Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Qualigen Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"QN-302","moa":"G4-quadruplex transcription","graph1":"Oncology","graph2":"IND Enabling","graph3":"Qualigen Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Qualigen Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Qualigen Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Qualigen Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Oligonucleotide","year":"2021","type":"Inapplicable","leadProduct":"AS1411","moa":"Nucleolin","graph1":"Oncology","graph2":"IND Enabling","graph3":"Qualigen Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Qualigen Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Qualigen Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Revolution Medicines","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"RMC-6291","moa":"KRAS G12C","graph1":"Oncology","graph2":"IND Enabling","graph3":"Revolution Medicines","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Revolution Medicines \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Revolution Medicines \/ Inapplicable"},{"orgOrder":0,"company":"Revolution Medicines","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"RMC-6291","moa":"KRAS G12C","graph1":"Oncology","graph2":"IND Enabling","graph3":"Revolution Medicines","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Revolution Medicines \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Revolution Medicines \/ Inapplicable"},{"orgOrder":0,"company":"Revolution Medicines","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"RMC-6291","moa":"KRAS G12C","graph1":"Oncology","graph2":"IND Enabling","graph3":"Revolution Medicines","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Revolution Medicines \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Revolution Medicines \/ Inapplicable"},{"orgOrder":0,"company":"Therapeutic Solutions","sponsor":"Res Nova Bio","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Demerger","leadProduct":"ValloVax","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"Therapeutic Solutions","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Therapeutic Solutions \/ Res Nova Bio","highestDevelopmentStatusID":"5","companyTruncated":"Therapeutic Solutions \/ Res Nova Bio"},{"orgOrder":0,"company":"Therapeutic Solutions","sponsor":"Veltmeyer MD","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Collaboration","leadProduct":"ValloVax","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"Therapeutic Solutions","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Therapeutic Solutions \/ Veltmeyer MD","highestDevelopmentStatusID":"5","companyTruncated":"Therapeutic Solutions \/ Veltmeyer MD"},{"orgOrder":0,"company":"Turnstone Biologics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"TIDAL-01","moa":"T-cell","graph1":"Oncology","graph2":"IND Enabling","graph3":"Turnstone Biologics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Turnstone Biologics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Turnstone Biologics \/ Inapplicable"},{"orgOrder":0,"company":"Calidi Biotherapeutics","sponsor":"Cirm","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Funding","leadProduct":"SNV1","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"Calidi Biotherapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Calidi Biotherapeutics \/ Cirm","highestDevelopmentStatusID":"5","companyTruncated":"Calidi Biotherapeutics \/ Cirm"},{"orgOrder":0,"company":"Calidi Biotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"SNV1","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"Calidi Biotherapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Calidi Biotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Calidi Biotherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"FibroGen","sponsor":"Regeneron Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Large Molecule","year":"2024","type":"Collaboration","leadProduct":"Cemiplimab","moa":"||Galectin-9","graph1":"Oncology","graph2":"IND Enabling","graph3":"FibroGen","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"FibroGen \/ Regeneron Pharmaceuticals","highestDevelopmentStatusID":"5","companyTruncated":"FibroGen \/ Regeneron Pharmaceuticals"},{"orgOrder":0,"company":"EvolveImmune Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2022","type":"Inapplicable","leadProduct":"EV-104","moa":"CD3","graph1":"Oncology","graph2":"IND Enabling","graph3":"EvolveImmune Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"EvolveImmune Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"EvolveImmune Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"EvolveImmune Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2022","type":"Inapplicable","leadProduct":"EV-104","moa":"CD3","graph1":"Oncology","graph2":"IND Enabling","graph3":"EvolveImmune Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"EvolveImmune Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"EvolveImmune Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"EvolveImmune Therapeutics","sponsor":"Pfizer Ventures","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2023","type":"Financing","leadProduct":"EV-104","moa":"CD3","graph1":"Oncology","graph2":"IND Enabling","graph3":"EvolveImmune Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"EvolveImmune Therapeutics \/ Pfizer Ventures","highestDevelopmentStatusID":"5","companyTruncated":"EvolveImmune Therapeutics \/ Pfizer Ventures"},{"orgOrder":0,"company":"Prelude Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"PRT3789","moa":"SMARCA2","graph1":"Oncology","graph2":"IND Enabling","graph3":"Prelude Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Prelude Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Prelude Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Fusion Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Radiolabelled Compounds","year":"2023","type":"Inapplicable","leadProduct":"225-Ac FPI-2068","moa":"Alpha-radiation","graph1":"Oncology","graph2":"IND Enabling","graph3":"Fusion Pharma","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Fusion Pharma \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Fusion Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Reverb Therapeutics","sponsor":"Amplitude Ventures","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CANADA","productType":"Antibody","year":"2025","type":"Financing","leadProduct":"AMP01","moa":"PD-1","graph1":"Oncology","graph2":"IND Enabling","graph3":"Reverb Therapeutics","amount2":0.01,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0.01,"dosageForm":"Undisclosed","sponsorNew":"Reverb Therapeutics \/ Amplitude Ventures","highestDevelopmentStatusID":"5","companyTruncated":"Reverb Therapeutics \/ Amplitude Ventures"},{"orgOrder":0,"company":"Adagene Suzhou Limited","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"ADG138","moa":"HER2\/CD3","graph1":"Oncology","graph2":"IND Enabling","graph3":"Adagene Suzhou Limited","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Adagene Suzhou Limited \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Adagene Suzhou Limited \/ Inapplicable"},{"orgOrder":0,"company":"Akeso","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"AK131","moa":"Adenosine receptor","graph1":"Oncology","graph2":"IND Enabling","graph3":"Akeso","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Akeso \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Akeso \/ Inapplicable"},{"orgOrder":0,"company":"BioRay Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Large Molecule","year":"2023","type":"Inapplicable","leadProduct":"BRY812","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"BioRay Pharmaceutical","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"BioRay Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"BioRay Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Dragon Boat Pharmaceutical","sponsor":"Sanyou Biopharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"BC008","moa":"CLDN18.2","graph1":"Oncology","graph2":"IND Enabling","graph3":"Dragon Boat Pharmaceutical","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dragon Boat Pharmaceutical \/ Sanyou Biopharmaceuticals","highestDevelopmentStatusID":"5","companyTruncated":"Dragon Boat Pharmaceutical \/ Sanyou Biopharmaceuticals"},{"orgOrder":0,"company":"Duality Biologics","sponsor":"Avenzo Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody-drug Conjugate","year":"2025","type":"Licensing Agreement","leadProduct":"DB-1418","moa":"EGFR\/HER3","graph1":"Oncology","graph2":"IND Enabling","graph3":"Duality Biologics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Duality Biologics \/ Avenzo Therapeutics","highestDevelopmentStatusID":"5","companyTruncated":"Duality Biologics \/ Avenzo Therapeutics"},{"orgOrder":0,"company":"Eucure Biopharma","sponsor":"Chipscreen NewWay Biosciences","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2023","type":"Licensing Agreement","leadProduct":"YH008","moa":"CTL4","graph1":"Oncology","graph2":"IND Enabling","graph3":"Eucure Biopharma","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Eucure Biopharma \/ Chipscreen NewWay Biosciences","highestDevelopmentStatusID":"5","companyTruncated":"Eucure Biopharma \/ Chipscreen NewWay Biosciences"},{"orgOrder":0,"company":"Fapon Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"FP002","moa":"CD47","graph1":"Oncology","graph2":"IND Enabling","graph3":"Fapon Biopharma","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Fapon Biopharma \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Fapon Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"Fapon Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Protein","year":"2025","type":"Inapplicable","leadProduct":"FP-008","moa":"PD-1\/IL-10M","graph1":"Oncology","graph2":"IND Enabling","graph3":"Fapon Biotech","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Fapon Biotech \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Fapon Biotech \/ Inapplicable"},{"orgOrder":0,"company":"GeneQuantum Healthcare","sponsor":"BrighGene Biomedical","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody-drug Conjugate","year":"2021","type":"Collaboration","leadProduct":"GQ1007","moa":"HER2","graph1":"Oncology","graph2":"IND Enabling","graph3":"GeneQuantum Healthcare","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"GeneQuantum Healthcare \/ BrighGene Biomedical","highestDevelopmentStatusID":"5","companyTruncated":"GeneQuantum Healthcare \/ BrighGene Biomedical"},{"orgOrder":0,"company":"GeneQuantum Healthcare","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody-drug Conjugate","year":"2020","type":"Inapplicable","leadProduct":"GQ1001","moa":"HER2","graph1":"Oncology","graph2":"IND Enabling","graph3":"GeneQuantum Healthcare","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"GeneQuantum Healthcare \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"GeneQuantum Healthcare \/ Inapplicable"},{"orgOrder":0,"company":"HighField Biopharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Large Molecule","year":"2024","type":"Inapplicable","leadProduct":"HF50","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"HighField Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"HighField Biopharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"HighField Biopharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"HighField Biopharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Large Molecule","year":"2024","type":"Inapplicable","leadProduct":"HF50","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"HighField Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"HighField Biopharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"HighField Biopharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"HUYA Bioscience International","sponsor":"Genhouse Bio","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"HBI-2376","moa":"SHP2","graph1":"Oncology","graph2":"IND Enabling","graph3":"HUYA Bioscience International","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"HUYA Bioscience International \/ Genhouse Bio","highestDevelopmentStatusID":"5","companyTruncated":"HUYA Bioscience International \/ Genhouse Bio"},{"orgOrder":0,"company":"I-Mab Biopharma","sponsor":"MorphoSys","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"MOR210","moa":"||C5a receptor","graph1":"Oncology","graph2":"IND Enabling","graph3":"I-Mab Biopharma","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"I-Mab Biopharma \/ MorphoSys","highestDevelopmentStatusID":"5","companyTruncated":"I-Mab Biopharma \/ MorphoSys"},{"orgOrder":0,"company":"IMPACT Therapeutics, Inc","sponsor":"Burning Rock Dx","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2021","type":"Collaboration","leadProduct":"IMP9064","moa":"||ATR","graph1":"Oncology","graph2":"IND Enabling","graph3":"IMPACT Therapeutics, Inc","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"IMPACT Therapeutics, Inc \/ Burning Rock Dx","highestDevelopmentStatusID":"5","companyTruncated":"IMPACT Therapeutics, Inc \/ Burning Rock Dx"},{"orgOrder":0,"company":"Jiangsu Simcere Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"SIM0237","moa":"PD-L1\/IL-15 receptor","graph1":"Oncology","graph2":"IND Enabling","graph3":"Jiangsu Simcere Pharmaceutical","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Jiangsu Simcere Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Jiangsu Simcere Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Laekna Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2025","type":"Inapplicable","leadProduct":"LAE120","moa":"USP-1","graph1":"Oncology","graph2":"IND Enabling","graph3":"Laekna Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Laekna Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Laekna Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Mabwell","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Large Molecule","year":"2023","type":"Inapplicable","leadProduct":"9MW2921","moa":"Apoptosis","graph1":"Oncology","graph2":"IND Enabling","graph3":"Mabwell","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Mabwell \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Mabwell \/ Inapplicable"},{"orgOrder":0,"company":"Medicilon","sponsor":"Oncotelic Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2025","type":"Partnership","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"Medicilon","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Medicilon \/ Oncotelic Therapeutics","highestDevelopmentStatusID":"5","companyTruncated":"Medicilon \/ Oncotelic Therapeutics"},{"orgOrder":0,"company":"MediLink Therapeutics","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Large Molecule","year":"2024","type":"Collaboration","leadProduct":"YL211","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"MediLink Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"MediLink Therapeutics \/ F. Hoffmann-La Roche","highestDevelopmentStatusID":"5","companyTruncated":"MediLink Therapeutics \/ F. Hoffmann-La Roche"},{"orgOrder":0,"company":"PharmaEssentia","sponsor":"Axis Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Cell and Gene therapy","year":"2020","type":"Collaboration","leadProduct":"TCRT-ESO-A2","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"PharmaEssentia","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"PharmaEssentia \/ Axis Therapeutics","highestDevelopmentStatusID":"5","companyTruncated":"PharmaEssentia \/ Axis Therapeutics"},{"orgOrder":0,"company":"Shanghai Junshi Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"JS006","moa":"||CD112R","graph1":"Oncology","graph2":"IND Enabling","graph3":"Shanghai Junshi Biosciences","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Shanghai Junshi Biosciences \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Shanghai Junshi Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Shenzhen Chipscreen Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"CS231295","moa":"Protein kinase","graph1":"Oncology","graph2":"IND Enabling","graph3":"Shenzhen Chipscreen Biosciences","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Shenzhen Chipscreen Biosciences \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Shenzhen Chipscreen Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Tianweiyuanhe Biomedical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Large Molecule","year":"2023","type":"Inapplicable","leadProduct":"A-337","moa":"EpCAM","graph1":"Oncology","graph2":"IND Enabling","graph3":"Tianweiyuanhe Biomedical","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Tianweiyuanhe Biomedical \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Tianweiyuanhe Biomedical \/ Inapplicable"},{"orgOrder":0,"company":"Axis Therapeutics","sponsor":"PharmaEssentia","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"HONG KONG","productType":"Cell and Gene therapy","year":"2020","type":"Collaboration","leadProduct":"TCRT-ESO-A2","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"Axis Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Axis Therapeutics \/ PharmaEssentia","highestDevelopmentStatusID":"5","companyTruncated":"Axis Therapeutics \/ PharmaEssentia"},{"orgOrder":0,"company":"Insilico Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"HONG KONG","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"ISM025","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"Insilico Medicine","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Insilico Medicine \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Insilico Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Sairopa","sponsor":"Exelixis","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"NETHERLANDS","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"ADU-1805","moa":"SIRP-alpha","graph1":"Oncology","graph2":"IND Enabling","graph3":"Sairopa","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sairopa \/ Exelixis","highestDevelopmentStatusID":"5","companyTruncated":"Sairopa \/ Exelixis"},{"orgOrder":0,"company":"Sairopa","sponsor":"Exelixis","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"NETHERLANDS","productType":"Antibody","year":"2022","type":"Collaboration","leadProduct":"ADU-1805","moa":"SIRP-alpha","graph1":"Oncology","graph2":"IND Enabling","graph3":"Sairopa","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sairopa \/ Exelixis","highestDevelopmentStatusID":"5","companyTruncated":"Sairopa \/ Exelixis"},{"orgOrder":0,"company":"Targovax","sponsor":"IOVaxis Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"NORWAY","productType":"Vaccine","year":"2021","type":"Licensing Agreement","leadProduct":"Apricoxib","moa":"KRAS","graph1":"Oncology","graph2":"IND Enabling","graph3":"Targovax","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Targovax \/ IOVaxis Therapeutics","highestDevelopmentStatusID":"5","companyTruncated":"Targovax \/ IOVaxis Therapeutics"},{"orgOrder":0,"company":"Targovax","sponsor":"Agenus","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"NORWAY","productType":"Vaccine","year":"2022","type":"Collaboration","leadProduct":"Apricoxib","moa":"||KRAS","graph1":"Oncology","graph2":"IND Enabling","graph3":"Targovax","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Targovax \/ Agenus","highestDevelopmentStatusID":"5","companyTruncated":"Targovax \/ Agenus"},{"orgOrder":0,"company":"Eutilex Inc","sponsor":"Samsung Biologics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"EU101","moa":"4-1BB","graph1":"Oncology","graph2":"IND Enabling","graph3":"Eutilex Inc","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Eutilex Inc \/ Samsung Biologics","highestDevelopmentStatusID":"5","companyTruncated":"Eutilex Inc \/ Samsung Biologics"},{"orgOrder":0,"company":"Peptron","sponsor":"Qilu Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Antibody-drug Conjugate","year":"2021","type":"Licensing Agreement","leadProduct":"PAb001-ADC","moa":"MUC1","graph1":"Oncology","graph2":"IND Enabling","graph3":"Peptron","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Peptron \/ Qilu Pharmaceutical","highestDevelopmentStatusID":"5","companyTruncated":"Peptron \/ Qilu Pharmaceutical"},{"orgOrder":0,"company":"Samsung Biologics","sponsor":"National OncoVenture","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"EU101","moa":"4-1BB","graph1":"Oncology","graph2":"IND Enabling","graph3":"Samsung Biologics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Samsung Biologics \/ National OncoVenture","highestDevelopmentStatusID":"5","companyTruncated":"Samsung Biologics \/ National OncoVenture"},{"orgOrder":0,"company":"Selecxine","sponsor":"GenScript ProBio","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"SLC-3010","moa":"IL-2 receptor","graph1":"Oncology","graph2":"IND Enabling","graph3":"Selecxine","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Selecxine \/ GenScript ProBio","highestDevelopmentStatusID":"5","companyTruncated":"Selecxine \/ GenScript ProBio"},{"orgOrder":0,"company":"Anaveon","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Other Large Molecule","year":"2024","type":"Inapplicable","leadProduct":"ANV600","moa":"||PD-1","graph1":"Oncology","graph2":"IND Enabling","graph3":"Anaveon","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Anaveon \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Anaveon \/ Inapplicable"},{"orgOrder":0,"company":"Bright Peak Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"BPT-143","moa":"IL-2-alpha receptor","graph1":"Oncology","graph2":"IND Enabling","graph3":"Bright Peak Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bright Peak Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Bright Peak Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Bright Peak Therapeutics","sponsor":"RA Capital Management","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Protein","year":"2021","type":"Series B Financing","leadProduct":"BPT-143","moa":"IL-2-alpha receptor","graph1":"Oncology","graph2":"IND Enabling","graph3":"Bright Peak Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bright Peak Therapeutics \/ RA Capital Management","highestDevelopmentStatusID":"5","companyTruncated":"Bright Peak Therapeutics \/ RA Capital Management"},{"orgOrder":0,"company":"Lonza Biologics Inc","sponsor":"aTyr Pharma","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Agreement","leadProduct":"ATYR2810","moa":"NRP2 receptor","graph1":"Oncology","graph2":"IND Enabling","graph3":"Lonza Biologics Inc","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Lonza Biologics Inc \/ aTyr Pharma","highestDevelopmentStatusID":"5","companyTruncated":"Lonza Biologics Inc \/ aTyr Pharma"},{"orgOrder":0,"company":"Lonza Group","sponsor":"Leucid Bio","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Cell and Gene therapy","year":"2021","type":"Collaboration","leadProduct":"LEU011","moa":"NKG2D receptor","graph1":"Oncology","graph2":"IND Enabling","graph3":"Lonza Group","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Lonza Group \/ Leucid Bio","highestDevelopmentStatusID":"5","companyTruncated":"Lonza Group \/ Leucid Bio"},{"orgOrder":0,"company":"Numab Therapeutics","sponsor":"3S Bio Inc","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Antibody","year":"2020","type":"Series B Financing","leadProduct":"ND021","moa":"4-1BB","graph1":"Oncology","graph2":"IND Enabling","graph3":"Numab Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Numab Therapeutics \/ 3S Bio Inc","highestDevelopmentStatusID":"5","companyTruncated":"Numab Therapeutics \/ 3S Bio Inc"},{"orgOrder":0,"company":"Acepodia","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"TAIWAN","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"ACE2016","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"Acepodia","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Acepodia \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Acepodia \/ Inapplicable"},{"orgOrder":0,"company":"OBI Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"TAIWAN","productType":"Other Large Molecule","year":"2024","type":"Inapplicable","leadProduct":"OBI-992","moa":"Trop2","graph1":"Oncology","graph2":"IND Enabling","graph3":"OBI Pharma","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"OBI Pharma \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"OBI Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Avacta Group","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Other Large Molecule","year":"2023","type":"Inapplicable","leadProduct":"AVA3996","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"Avacta Group","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Avacta Group \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Avacta Group \/ Inapplicable"},{"orgOrder":0,"company":"Exscientia","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"EXS74539","moa":"LSD1","graph1":"Oncology","graph2":"IND Enabling","graph3":"Exscientia","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Exscientia \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Exscientia \/ Inapplicable"},{"orgOrder":0,"company":"Mestag Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Other Large Molecule","year":"2024","type":"Inapplicable","leadProduct":"M300","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"Mestag Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Mestag Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Mestag Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Oxford Biotherapeutics","sponsor":"Genmab","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Antibody","year":"2022","type":"Licensing Agreement","leadProduct":"OBT700","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"Oxford Biotherapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Oxford Biotherapeutics \/ Genmab","highestDevelopmentStatusID":"5","companyTruncated":"Oxford Biotherapeutics \/ Genmab"},{"orgOrder":0,"company":"Oxilio","sponsor":"Quotient Sciences","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"OXL001","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"Oxilio","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Oxilio \/ Quotient Sciences","highestDevelopmentStatusID":"5","companyTruncated":"Oxilio \/ Quotient Sciences"},{"orgOrder":0,"company":"Pheon Therapeutics","sponsor":"Brandon Capital","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Antibody-drug Conjugate","year":"2022","type":"Series A Financing","leadProduct":"PHN-010","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"Pheon Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pheon Therapeutics \/ Brandon Capital","highestDevelopmentStatusID":"5","companyTruncated":"Pheon Therapeutics \/ Brandon Capital"},{"orgOrder":0,"company":"Pheon Therapeutics","sponsor":"TCGX","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Antibody-drug Conjugate","year":"2024","type":"Series B Financing","leadProduct":"PHN-010","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"Pheon Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pheon Therapeutics \/ TCGX","highestDevelopmentStatusID":"5","companyTruncated":"Pheon Therapeutics \/ TCGX"},{"orgOrder":0,"company":"Point Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Radiolabelled Compounds","year":"2022","type":"Inapplicable","leadProduct":"177-Lu PNT2004","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"Point Biopharma","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Point Biopharma \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Point Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"Point Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Radiolabelled Compounds","year":"2021","type":"Inapplicable","leadProduct":"177-Lu PNT2004","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"Point Biopharma","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Point Biopharma \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Point Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"Georgiamune","sponsor":"General Catalyst","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Large Molecule","year":"2023","type":"Series A Financing","leadProduct":"GIM-122","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"Georgiamune","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Georgiamune \/ General Catalyst","highestDevelopmentStatusID":"5","companyTruncated":"Georgiamune \/ General Catalyst"},{"orgOrder":0,"company":"NexImmune","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"NEXI-003","moa":"CD3\/4","graph1":"Oncology","graph2":"IND Enabling","graph3":"NexImmune","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"NexImmune \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"NexImmune \/ Inapplicable"},{"orgOrder":0,"company":"Salubris Biotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Large Molecule","year":"2024","type":"Inapplicable","leadProduct":"JK06","moa":"5T4 protein","graph1":"Oncology","graph2":"IND Enabling","graph3":"Salubris Biotherapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Salubris Biotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Salubris Biotherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Affini-T Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"AFNT-111","moa":"KRAS G12V","graph1":"Oncology","graph2":"IND Enabling","graph3":"Affini-T Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Affini-T Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Affini-T Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Centessa Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"LB101","moa":"PD-L1","graph1":"Oncology","graph2":"IND Enabling","graph3":"Centessa Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Centessa Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Centessa Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Codiak BioSciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Oligonucleotide","year":"2021","type":"Inapplicable","leadProduct":"exoASO-STAT6","moa":"STAT6","graph1":"Oncology","graph2":"IND Enabling","graph3":"Codiak BioSciences","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Codiak BioSciences \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Codiak BioSciences \/ Inapplicable"},{"orgOrder":0,"company":"Compass Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"CTX-8371","moa":"PD-L1","graph1":"Oncology","graph2":"IND Enabling","graph3":"Compass Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Compass Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Compass Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Compass Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"CTX-8371","moa":"PD-L1","graph1":"Oncology","graph2":"IND Enabling","graph3":"Compass Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Compass Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Compass Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Editas Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"EDIT-201","moa":"Immunostimulant","graph1":"Oncology","graph2":"IND Enabling","graph3":"Editas Medicine","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Editas Medicine \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Editas Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Editas Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"EDIT-201","moa":"Immunostimulant","graph1":"Oncology","graph2":"IND Enabling","graph3":"Editas Medicine","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Editas Medicine \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Editas Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Genocea","sponsor":"Brookline Capital Markets","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Private Placement","leadProduct":"GEN-011","moa":"CD4 T-cell","graph1":"Oncology","graph2":"IND Enabling","graph3":"Genocea","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Genocea \/ Brookline Capital Markets","highestDevelopmentStatusID":"5","companyTruncated":"Genocea \/ Brookline Capital Markets"},{"orgOrder":0,"company":"Genocea","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"GEN-011","moa":"CD4 T-cell","graph1":"Oncology","graph2":"IND Enabling","graph3":"Genocea","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Genocea \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Genocea \/ Inapplicable"},{"orgOrder":0,"company":"Genocea","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"GEN-011","moa":"CD4 T-cell","graph1":"Oncology","graph2":"IND Enabling","graph3":"Genocea","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Genocea \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Genocea \/ Inapplicable"},{"orgOrder":0,"company":"HiFiBiO Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"HFB200603","moa":"||BLTA","graph1":"Oncology","graph2":"IND Enabling","graph3":"HiFiBiO Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"HiFiBiO Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"HiFiBiO Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"HiFiBiO Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"HFB301001","moa":"OX40 receptor","graph1":"Oncology","graph2":"IND Enabling","graph3":"HiFiBiO Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"HiFiBiO Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"HiFiBiO Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"HiFiBiO Therapeutics","sponsor":"Mirae Asset Financial Group","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Series D Financing","leadProduct":"HFB200301","moa":"TNF2 receptor","graph1":"Oncology","graph2":"IND Enabling","graph3":"HiFiBiO Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"HiFiBiO Therapeutics \/ Mirae Asset Financial Group","highestDevelopmentStatusID":"5","companyTruncated":"HiFiBiO Therapeutics \/ Mirae Asset Financial Group"},{"orgOrder":0,"company":"Jounce Therapeutics","sponsor":"Gilead Sciences","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Licensing Agreement","leadProduct":"JTX-1811","moa":"CCR8","graph1":"Oncology","graph2":"IND Enabling","graph3":"Jounce Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Jounce Therapeutics \/ Gilead Sciences","highestDevelopmentStatusID":"5","companyTruncated":"Jounce Therapeutics \/ Gilead Sciences"},{"orgOrder":0,"company":"Nona Biosciences","sponsor":"Pfizer Inc","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Large Molecule","year":"2023","type":"Licensing Agreement","leadProduct":"HBM9033","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"Nona Biosciences","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Nona Biosciences \/ Pfizer Inc","highestDevelopmentStatusID":"5","companyTruncated":"Nona Biosciences \/ Pfizer Inc"},{"orgOrder":0,"company":"Pyxis Oncology","sponsor":"The University of Chicago","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2021","type":"Public Offering","leadProduct":"PYX-201","moa":"Fibronectin EDB","graph1":"Oncology","graph2":"IND Enabling","graph3":"Pyxis Oncology","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pyxis Oncology \/ The University of Chicago","highestDevelopmentStatusID":"5","companyTruncated":"Pyxis Oncology \/ The University of Chicago"},{"orgOrder":0,"company":"RootPath","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"InfiniTIL","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"RootPath","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"RootPath \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"RootPath \/ Inapplicable"},{"orgOrder":0,"company":"Tango Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"TNG260","moa":"||CoREST-HDAC","graph1":"Oncology","graph2":"IND Enabling","graph3":"Tango Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Tango Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Tango Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Tasca Therapeutics","sponsor":"Regeneron Ventures","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Series A Financing","leadProduct":"CAS 77168-63-9","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"Tasca Therapeutics","amount2":0.050000000000000003,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0.050000000000000003,"dosageForm":"Undisclosed","sponsorNew":"Tasca Therapeutics \/ Regeneron Ventures","highestDevelopmentStatusID":"5","companyTruncated":"Tasca Therapeutics \/ Regeneron Ventures"},{"orgOrder":0,"company":"TScan Therapeutics","sponsor":"Blackrock","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Series C Financing","leadProduct":"TSC-100","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"TScan Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"TScan Therapeutics \/ Blackrock","highestDevelopmentStatusID":"5","companyTruncated":"TScan Therapeutics \/ Blackrock"},{"orgOrder":0,"company":"TScan Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"TSC-204-A0201","moa":"MAGE-A1","graph1":"Oncology","graph2":"IND Enabling","graph3":"TScan Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"TScan Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"TScan Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"TScan Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"TSC-200-A02","moa":"MHC","graph1":"Oncology","graph2":"IND Enabling","graph3":"TScan Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"TScan Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"TScan Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"TScan Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"TSC-200-A02","moa":"MHC","graph1":"Oncology","graph2":"IND Enabling","graph3":"TScan Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"TScan Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"TScan Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Zumutor Biologics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"ZM008","moa":"LLT1 antigen","graph1":"Oncology","graph2":"IND Enabling","graph3":"Zumutor Biologics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Zumutor Biologics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Zumutor Biologics \/ Inapplicable"},{"orgOrder":0,"company":"Centessa Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"LB101","moa":"PD-L1","graph1":"Oncology","graph2":"IND Enabling","graph3":"Centessa Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Centessa Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Centessa Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Centessa Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"LB101","moa":"PD-L1","graph1":"Oncology","graph2":"IND Enabling","graph3":"Centessa Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Centessa Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Centessa Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Genocea","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"GEN-011","moa":"CD4 T-cell","graph1":"Oncology","graph2":"IND Enabling","graph3":"Genocea","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Genocea \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Genocea \/ Inapplicable"},{"orgOrder":0,"company":"HiFiBiO Therapeutics","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Agreement","leadProduct":"HFB200603","moa":"||BLTA","graph1":"Oncology","graph2":"IND Enabling","graph3":"HiFiBiO Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"HiFiBiO Therapeutics \/ Novartis Pharmaceuticals Corporation","highestDevelopmentStatusID":"5","companyTruncated":"HiFiBiO Therapeutics \/ Novartis Pharmaceuticals Corporation"},{"orgOrder":0,"company":"Jounce Therapeutics","sponsor":"Gilead Sciences","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Licensing Agreement","leadProduct":"JTX-1811","moa":"CCR8","graph1":"Oncology","graph2":"IND Enabling","graph3":"Jounce Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Jounce Therapeutics \/ Gilead Sciences","highestDevelopmentStatusID":"5","companyTruncated":"Jounce Therapeutics \/ Gilead Sciences"},{"orgOrder":0,"company":"Jounce Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"JTX-1811","moa":"CCR8","graph1":"Oncology","graph2":"IND Enabling","graph3":"Jounce Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Jounce Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Jounce Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Pyxis Oncology","sponsor":"Arix Bioscience Plc","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2021","type":"Series B Financing","leadProduct":"PYX-201","moa":"Fibronectin EDB","graph1":"Oncology","graph2":"IND Enabling","graph3":"Pyxis Oncology","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pyxis Oncology \/ Arix Bioscience Plc","highestDevelopmentStatusID":"5","companyTruncated":"Pyxis Oncology \/ Arix Bioscience Plc"},{"orgOrder":0,"company":"Pyxis Oncology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2021","type":"Inapplicable","leadProduct":"PYX-201","moa":"Fibronectin EDB","graph1":"Oncology","graph2":"IND Enabling","graph3":"Pyxis Oncology","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pyxis Oncology \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Pyxis Oncology \/ Inapplicable"},{"orgOrder":0,"company":"Pyxis Oncology","sponsor":"Pfizer Inc","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2021","type":"Financing","leadProduct":"PYX-201","moa":"Fibronectin EDB","graph1":"Oncology","graph2":"IND Enabling","graph3":"Pyxis Oncology","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pyxis Oncology \/ Pfizer Inc","highestDevelopmentStatusID":"5","companyTruncated":"Pyxis Oncology \/ Pfizer Inc"},{"orgOrder":0,"company":"Zumutor Biologics","sponsor":"Catalent Pharma Solutions","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Collaboration","leadProduct":"ZM008","moa":"LLT1 antigen","graph1":"Oncology","graph2":"IND Enabling","graph3":"Zumutor Biologics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Zumutor Biologics \/ Catalent Pharma Solutions","highestDevelopmentStatusID":"5","companyTruncated":"Zumutor Biologics \/ Catalent Pharma Solutions"},{"orgOrder":0,"company":"Hillstream BioPharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Salinomycin","moa":"Ferroptosis","graph1":"Oncology","graph2":"IND Enabling","graph3":"Hillstream BioPharma","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hillstream BioPharma \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Hillstream BioPharma \/ Inapplicable"},{"orgOrder":0,"company":"Hillstream BioPharma","sponsor":"Sapien Biosciences","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Collaboration","leadProduct":"Salinomycin","moa":"||Ferroptosis","graph1":"Oncology","graph2":"IND Enabling","graph3":"Hillstream BioPharma","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hillstream BioPharma \/ Sapien Biosciences","highestDevelopmentStatusID":"5","companyTruncated":"Hillstream BioPharma \/ Sapien Biosciences"},{"orgOrder":0,"company":"Hillstream BioPharma","sponsor":"Thinkequity","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Public Offering","leadProduct":"Salinomycin","moa":"Ferroptosis","graph1":"Oncology","graph2":"IND Enabling","graph3":"Hillstream BioPharma","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hillstream BioPharma \/ Thinkequity","highestDevelopmentStatusID":"5","companyTruncated":"Hillstream BioPharma \/ Thinkequity"},{"orgOrder":0,"company":"Athenex","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"TCRT-ESO-A2","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"Athenex","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Athenex \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Athenex \/ Inapplicable"},{"orgOrder":0,"company":"Hoth Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"HT-KIT","moa":"c-KIT receptor","graph1":"Oncology","graph2":"IND Enabling","graph3":"Hoth Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hoth Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Hoth Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Hoth Therapeutics","sponsor":"OnTargetx","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2025","type":"Collaboration","leadProduct":"HT-KIT","moa":"c-KIT receptor","graph1":"Oncology","graph2":"IND Enabling","graph3":"Hoth Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hoth Therapeutics \/ OnTargetx","highestDevelopmentStatusID":"5","companyTruncated":"Hoth Therapeutics \/ OnTargetx"},{"orgOrder":0,"company":"MiNK Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"MiNK-413","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"MiNK Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"MiNK Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"MiNK Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Neogene","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"NT-125","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"Neogene","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Neogene \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Neogene \/ Inapplicable"},{"orgOrder":0,"company":"Nuvation Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"NUV-1511","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"Nuvation Bio","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Nuvation Bio \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Nuvation Bio \/ Inapplicable"},{"orgOrder":0,"company":"Sapience Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Peptide","year":"2023","type":"Inapplicable","leadProduct":"ST316","moa":"Wnt\/beta-catenin","graph1":"Oncology","graph2":"IND Enabling","graph3":"Sapience Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sapience Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Sapience Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Seed Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"ST-01156","moa":"RBM39","graph1":"Oncology","graph2":"IND Enabling","graph3":"Seed Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Seed Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Seed Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Immorna","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Large Molecule","year":"2024","type":"Inapplicable","leadProduct":"JCXH-211","moa":"||IL-12 receptor","graph1":"Oncology","graph2":"IND Enabling","graph3":"Immorna","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Immorna \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Immorna \/ Inapplicable"},{"orgOrder":0,"company":"KBI Biopharma","sponsor":"BITT","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Agreement","leadProduct":"BITR2101","moa":"TNF2 receptor","graph1":"Oncology","graph2":"IND Enabling","graph3":"KBI Biopharma","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"KBI Biopharma \/ BITT","highestDevelopmentStatusID":"5","companyTruncated":"KBI Biopharma \/ BITT"},{"orgOrder":0,"company":"Miltenyi Biotec","sponsor":"Syena","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"GERMANY","productType":"Cell and Gene therapy","year":"2023","type":"Licensing Agreement","leadProduct":"SY-001","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"Miltenyi Biotec","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Miltenyi Biotec \/ Syena","highestDevelopmentStatusID":"5","companyTruncated":"Miltenyi Biotec \/ Syena"},{"orgOrder":0,"company":"Carisma Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"CT-0525","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"Carisma Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Carisma Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Carisma Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Immunome","sponsor":"Enavate Sciences","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Large Molecule","year":"2023","type":"Private Placement","leadProduct":"IMM20320","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"Immunome","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Immunome \/ Enavate Sciences","highestDevelopmentStatusID":"5","companyTruncated":"Immunome \/ Enavate Sciences"},{"orgOrder":0,"company":"Integral Molecular","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"CTIM-76","moa":"CLDN-6\/CD3","graph1":"Oncology","graph2":"IND Enabling","graph3":"Integral Molecular","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Integral Molecular \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Integral Molecular \/ Inapplicable"},{"orgOrder":0,"company":"Affimed","sponsor":"Roivant Sciences","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"GERMANY","productType":"Protein","year":"2020","type":"Collaboration","leadProduct":"AFM32","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"Affimed","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Affimed \/ Roivant Sciences","highestDevelopmentStatusID":"5","companyTruncated":"Affimed \/ Roivant Sciences"},{"orgOrder":0,"company":"Bellicum Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"BPX-603","moa":"MyD88\/CD40","graph1":"Oncology","graph2":"IND Enabling","graph3":"Bellicum Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bellicum Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Bellicum Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Dialectic Therapeutics","sponsor":"Cancer Prevention and Research Institute of Texas","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Funding","leadProduct":"DT2216","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"Dialectic Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dialectic Therapeutics \/ Cancer Prevention and Research Institute of Texas","highestDevelopmentStatusID":"5","companyTruncated":"Dialectic Therapeutics \/ Cancer Prevention and Research Institute of Texas"},{"orgOrder":0,"company":"Kiromic BioPharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"ALEXIS-PRO-1","moa":"PD-L1","graph1":"Oncology","graph2":"IND Enabling","graph3":"Kiromic BioPharma","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Kiromic BioPharma \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Kiromic BioPharma \/ Inapplicable"},{"orgOrder":0,"company":"Kiromic BioPharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"Deltacel","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"Kiromic BioPharma","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Kiromic BioPharma \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Kiromic BioPharma \/ Inapplicable"},{"orgOrder":0,"company":"Kiromic BioPharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"ALEXIS-ISO-1","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"Kiromic BioPharma","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Kiromic BioPharma \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Kiromic BioPharma \/ Inapplicable"},{"orgOrder":0,"company":"Molecular Templates","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2022","type":"Inapplicable","leadProduct":"MT-8421","moa":"CTLA-4","graph1":"Oncology","graph2":"IND Enabling","graph3":"Molecular Templates","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Molecular Templates \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Molecular Templates \/ Inapplicable"},{"orgOrder":0,"company":"Molecular Templates","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2023","type":"Inapplicable","leadProduct":"MT-8421","moa":"CTLA-4","graph1":"Oncology","graph2":"IND Enabling","graph3":"Molecular Templates","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Molecular Templates \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Molecular Templates \/ Inapplicable"},{"orgOrder":0,"company":"BITT","sponsor":"BeiGene","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Collaboration","leadProduct":"BITR2101","moa":"||TNF2 receptor","graph1":"Oncology","graph2":"IND Enabling","graph3":"BITT","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"BITT \/ BeiGene","highestDevelopmentStatusID":"5","companyTruncated":"BITT \/ BeiGene"},{"orgOrder":0,"company":"AGC Biologics","sponsor":"Medigene","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Agreement","leadProduct":"MDG1015","moa":"||NY-ESO-1\/LAGE-1a","graph1":"Oncology","graph2":"IND Enabling","graph3":"AGC Biologics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AGC Biologics \/ Medigene","highestDevelopmentStatusID":"5","companyTruncated":"AGC Biologics \/ Medigene"},{"orgOrder":0,"company":"Kineta","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"KVA12.1","moa":"||VISTA","graph1":"Oncology","graph2":"IND Enabling","graph3":"Kineta","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Kineta \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Kineta \/ Inapplicable"},{"orgOrder":0,"company":"Link Immunotherapeutics","sponsor":"Context Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Large Molecule","year":"2024","type":"Acquisition","leadProduct":"CT-95","moa":"MSLN\/CD3","graph1":"Oncology","graph2":"IND Enabling","graph3":"Link Immunotherapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Link Immunotherapeutics \/ Context Therapeutics","highestDevelopmentStatusID":"5","companyTruncated":"Link Immunotherapeutics \/ Context Therapeutics"},{"orgOrder":0,"company":"Kineta","sponsor":"Cheongbo Industrial","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Financing","leadProduct":"KVA12.1","moa":"VISTA","graph1":"Oncology","graph2":"IND Enabling","graph3":"Kineta","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Kineta \/ Cheongbo Industrial","highestDevelopmentStatusID":"5","companyTruncated":"Kineta \/ Cheongbo Industrial"},{"orgOrder":0,"company":"Avstera Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"AVS100","moa":"||Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"Avstera Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Avstera Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Avstera Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Alentis Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Other Large Molecule","year":"2024","type":"Inapplicable","leadProduct":"ALE.P02","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"Alentis Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Alentis Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Alentis Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Undisclosed","sponsor":"MOMA Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Other Small Molecule","year":"2025","type":"Licensing Agreement","leadProduct":"MOMA-989","moa":"PARP-1","graph1":"Oncology","graph2":"IND Enabling","graph3":"Undisclosed","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Undisclosed \/ MOMA Therapeutics","highestDevelopmentStatusID":"5","companyTruncated":"Undisclosed \/ MOMA Therapeutics"},{"orgOrder":0,"company":"Allomek","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"CIP-137401","moa":"MEK receptor","graph1":"Oncology","graph2":"IND Enabling","graph3":"Allomek","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Allomek \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Allomek \/ Inapplicable"},{"orgOrder":0,"company":"Allomek","sponsor":"Camac Partners","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Acquisition","leadProduct":"CIP-137401","moa":"MEK receptor","graph1":"Oncology","graph2":"IND Enabling","graph3":"Allomek","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Allomek \/ Camac Partners","highestDevelopmentStatusID":"5","companyTruncated":"Allomek \/ Camac Partners"},{"orgOrder":0,"company":"Pasithea Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"PAS-004","moa":"MEK1\/2 receptor","graph1":"Oncology","graph2":"IND Enabling","graph3":"Pasithea Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pasithea Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Pasithea Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Pasithea Therapeutics","sponsor":"WuXi AppTec","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Agreement","leadProduct":"PAS-004","moa":"MEK1\/2 receptor","graph1":"Oncology","graph2":"IND Enabling","graph3":"Pasithea Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pasithea Therapeutics \/ WuXi AppTec","highestDevelopmentStatusID":"5","companyTruncated":"Pasithea Therapeutics \/ WuXi AppTec"},{"orgOrder":0,"company":"UroGen Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Imiquimod","moa":"||CTLA-4","graph1":"Oncology","graph2":"IND Enabling","graph3":"UroGen Pharma","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravesical Solution","sponsorNew":"UroGen Pharma \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"UroGen Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Flare Therapeutics","sponsor":"GordonMD Global Investments","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Series B Financing","leadProduct":"3-(5,7-difluoro-4-oxo-1H-quinolin-2-yl)-4-methylsulfonylbenzonitrile","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"Flare Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Flare Therapeutics \/ GordonMD Global Investments","highestDevelopmentStatusID":"5","companyTruncated":"Flare Therapeutics \/ GordonMD Global Investments"},{"orgOrder":0,"company":"Flare Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"3-(5,7-difluoro-4-oxo-1H-quinolin-2-yl)-4-methylsulfonylbenzonitrile","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"Flare Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Flare Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Flare Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Prokarium","sponsor":"Ginkgo Bioworks","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2023","type":"Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"Prokarium","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Prokarium \/ Ginkgo Bioworks","highestDevelopmentStatusID":"5","companyTruncated":"Prokarium \/ Ginkgo Bioworks"},{"orgOrder":0,"company":"SURGE Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Resiquimod","moa":"Toll-like-7\/Toll-like-8 receptor","graph1":"Oncology","graph2":"IND Enabling","graph3":"SURGE Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"SURGE Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"SURGE Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Ayala Pharmaceuticals","sponsor":"OS Therapies","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2021","type":"Licensing Agreement","leadProduct":"Attenuted Listeria Monocytogene","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"Ayala Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ayala Pharmaceuticals \/ OS Therapies","highestDevelopmentStatusID":"5","companyTruncated":"Ayala Pharmaceuticals \/ OS Therapies"},{"orgOrder":0,"company":"Ayala Pharmaceuticals","sponsor":"OS Therapies","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2021","type":"Licensing Agreement","leadProduct":"Attenuted Listeria Monocytogene","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"Ayala Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ayala Pharmaceuticals \/ OS Therapies","highestDevelopmentStatusID":"5","companyTruncated":"Ayala Pharmaceuticals \/ OS Therapies"},{"orgOrder":0,"company":"Umoja Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"UB-TT170","moa":"||Folate-alpha receptor","graph1":"Oncology","graph2":"IND Enabling","graph3":"Umoja Biopharma","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Umoja Biopharma \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Umoja Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"Umoja Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"UB-TT170","moa":"Folate-alpha receptor","graph1":"Oncology","graph2":"IND Enabling","graph3":"Umoja Biopharma","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Umoja Biopharma \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Umoja Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"Umoja Biopharma","sponsor":"SoftBank Vision","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Series B Financing","leadProduct":"UB-TT170","moa":"Folate-alpha receptor","graph1":"Oncology","graph2":"IND Enabling","graph3":"Umoja Biopharma","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Umoja Biopharma \/ SoftBank Vision","highestDevelopmentStatusID":"5","companyTruncated":"Umoja Biopharma \/ SoftBank Vision"},{"orgOrder":0,"company":"Bio Elpida","sponsor":"Biovaxys","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"BVX-0918A","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"Bio Elpida","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Bio Elpida \/ Biovaxys","highestDevelopmentStatusID":"5","companyTruncated":"Bio Elpida \/ Biovaxys"},{"orgOrder":0,"company":"Bio Elpida","sponsor":"Biovaxys","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"FRANCE","productType":"Vaccine","year":"2021","type":"Partnership","leadProduct":"BVX-0918A","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"Bio Elpida","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Bio Elpida \/ Biovaxys","highestDevelopmentStatusID":"5","companyTruncated":"Bio Elpida \/ Biovaxys"},{"orgOrder":0,"company":"Bio Elpida","sponsor":"Biovaxys","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"FRANCE","productType":"Vaccine","year":"2021","type":"Agreement","leadProduct":"BVX-0918A","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"Bio Elpida","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Bio Elpida \/ Biovaxys","highestDevelopmentStatusID":"5","companyTruncated":"Bio Elpida \/ Biovaxys"},{"orgOrder":0,"company":"Merck & Co","sponsor":"TILT Biotherapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Microorganism","year":"2021","type":"Collaboration","leadProduct":"Igrelimogene Litadenorepvec","moa":"||TNF-alpha\/IL-2 receptor","graph1":"Oncology","graph2":"IND Enabling","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Merck & Co \/ TILT Biotherapeutics","highestDevelopmentStatusID":"5","companyTruncated":"Merck & Co \/ TILT Biotherapeutics"},{"orgOrder":0,"company":"INmune Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"INKmune","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"INmune Bio","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"INmune Bio \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"INmune Bio \/ Inapplicable"},{"orgOrder":0,"company":"INmune Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"INKmune","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"INmune Bio","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"INmune Bio \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"INmune Bio \/ Inapplicable"},{"orgOrder":0,"company":"Aprea Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"APR-1051","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"Aprea Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Aprea Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Aprea Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Aprea Therapeutics","sponsor":"Maxim Group LLC","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Private Placement","leadProduct":"APR-1051","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"Aprea Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Aprea Therapeutics \/ Maxim Group LLC","highestDevelopmentStatusID":"5","companyTruncated":"Aprea Therapeutics \/ Maxim Group LLC"},{"orgOrder":0,"company":"Aprea Therapeutics","sponsor":"The Division of Cancer Treatment and Diagnosis","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Funding","leadProduct":"ATRN-119","moa":"ATR","graph1":"Oncology","graph2":"IND Enabling","graph3":"Aprea Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Aprea Therapeutics \/ The Division of Cancer Treatment and Diagnosis","highestDevelopmentStatusID":"5","companyTruncated":"Aprea Therapeutics \/ The Division of Cancer Treatment and Diagnosis"},{"orgOrder":0,"company":"Ideaya Biosciences","sponsor":"Cancer Research Uk","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Licensing Agreement","leadProduct":"IDE161","moa":"PARG","graph1":"Oncology","graph2":"IND Enabling","graph3":"Ideaya Biosciences","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ideaya Biosciences \/ Cancer Research Uk","highestDevelopmentStatusID":"5","companyTruncated":"Ideaya Biosciences \/ Cancer Research Uk"},{"orgOrder":0,"company":"Zymeworks","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Other Large Molecule","year":"2024","type":"Inapplicable","leadProduct":"ZW191","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"Zymeworks","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Zymeworks \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Zymeworks \/ Inapplicable"},{"orgOrder":0,"company":"NK CellTech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"NK010","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"NK CellTech","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"NK CellTech \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"NK CellTech \/ Inapplicable"},{"orgOrder":0,"company":"Gadeta","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"NETHERLANDS","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"GDT002","moa":"Gamma-delta-T-cell","graph1":"Oncology","graph2":"IND Enabling","graph3":"Gadeta","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Gadeta \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Gadeta \/ Inapplicable"},{"orgOrder":0,"company":"Engine Biosciences","sponsor":"Polaris Partners","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SINGAPORE","productType":"Other Small Molecule","year":"2023","type":"Series A Financing","leadProduct":"ENB-812","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"Engine Biosciences","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Engine Biosciences \/ Polaris Partners","highestDevelopmentStatusID":"5","companyTruncated":"Engine Biosciences \/ Polaris Partners"},{"orgOrder":0,"company":"OnCusp Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2023","type":"Inapplicable","leadProduct":"CUSP06","moa":"CDH6","graph1":"Oncology","graph2":"IND Enabling","graph3":"OnCusp Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"OnCusp Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"OnCusp Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"OnCusp Therapeutics","sponsor":"Organovo Holdings","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2024","type":"Series A Financing","leadProduct":"CUSP06","moa":"CDH6","graph1":"Oncology","graph2":"IND Enabling","graph3":"OnCusp Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"OnCusp Therapeutics \/ Organovo Holdings","highestDevelopmentStatusID":"5","companyTruncated":"OnCusp Therapeutics \/ Organovo Holdings"},{"orgOrder":0,"company":"Carina Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"CNA3103","moa":"LGR5","graph1":"Oncology","graph2":"IND Enabling","graph3":"Carina Biotech","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Carina Biotech \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Carina Biotech \/ Inapplicable"},{"orgOrder":0,"company":"Cartherics","sponsor":"Shunxi Holding Group","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Cell and Gene therapy","year":"2023","type":"Licensing Agreement","leadProduct":"CTH-004","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"Cartherics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Cartherics \/ Shunxi Holding Group","highestDevelopmentStatusID":"5","companyTruncated":"Cartherics \/ Shunxi Holding Group"},{"orgOrder":0,"company":"Outpace Bio","sponsor":"RA Capital Management","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Series B Financing","leadProduct":"OPB-101","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"Outpace Bio","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Outpace Bio \/ RA Capital Management","highestDevelopmentStatusID":"5","companyTruncated":"Outpace Bio \/ RA Capital Management"},{"orgOrder":0,"company":"Jacobio Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"JAB-30300","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"Jacobio Pharma","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Jacobio Pharma \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Jacobio Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Lamassu Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"SA53-OS","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"Lamassu Pharma","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Lamassu Pharma \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Lamassu Pharma \/ Inapplicable"},{"orgOrder":0,"company":"ImPact Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Cytotoxic Drug","year":"2023","type":"Inapplicable","leadProduct":"Padeliporfin","moa":"Lipid peroxidation","graph1":"Oncology","graph2":"IND Enabling","graph3":"ImPact Biotech","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"ImPact Biotech \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"ImPact Biotech \/ Inapplicable"},{"orgOrder":0,"company":"Lantern Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Irofulven","moa":"DNA adduct","graph1":"Oncology","graph2":"IND Enabling","graph3":"Lantern Pharma","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Lantern Pharma \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Lantern Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Lantern Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Irofulven","moa":"DNA adduct","graph1":"Oncology","graph2":"IND Enabling","graph3":"Lantern Pharma","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Lantern Pharma \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Lantern Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Lantern Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Irofulven","moa":"DNA adduct","graph1":"Oncology","graph2":"IND Enabling","graph3":"Lantern Pharma","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Lantern Pharma \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Lantern Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Lantern Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Irofulven","moa":"DNA adduct","graph1":"Oncology","graph2":"IND Enabling","graph3":"Lantern Pharma","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Lantern Pharma \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Lantern Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Lantern Pharma","sponsor":"National Cancer Institute","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Expanded Collaboration","leadProduct":"Irofulven","moa":"DNA adduct","graph1":"Oncology","graph2":"IND Enabling","graph3":"Lantern Pharma","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Lantern Pharma \/ National Cancer Institute","highestDevelopmentStatusID":"5","companyTruncated":"Lantern Pharma \/ National Cancer Institute"},{"orgOrder":0,"company":"Phanes Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"PT886","moa":"CLDN18.2","graph1":"Oncology","graph2":"IND Enabling","graph3":"Phanes Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Phanes Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Phanes Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"MindRank","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"MRANK-106","moa":"WEE1\/YES1 kinase","graph1":"Oncology","graph2":"IND Enabling","graph3":"MindRank","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"MindRank \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"MindRank \/ Inapplicable"},{"orgOrder":0,"company":"Brown University","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Funding","leadProduct":"ONC212","moa":"GPR132","graph1":"Oncology","graph2":"IND Enabling","graph3":"Brown University","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Brown University \/ Undisclosed","highestDevelopmentStatusID":"5","companyTruncated":"Brown University \/ Undisclosed"},{"orgOrder":0,"company":"National Cancer Institute","sponsor":"Elicio Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Collaboration","leadProduct":"ELI-002","moa":"KRAS","graph1":"Oncology","graph2":"IND Enabling","graph3":"National Cancer Institute","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"National Cancer Institute \/ Elicio Therapeutics","highestDevelopmentStatusID":"5","companyTruncated":"National Cancer Institute \/ Elicio Therapeutics"},{"orgOrder":0,"company":"BioAtla","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Large Molecule","year":"2024","type":"Inapplicable","leadProduct":"BA3361","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"BioAtla","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"BioAtla \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"BioAtla \/ Inapplicable"},{"orgOrder":0,"company":"Qualigen Therapeutics","sponsor":"Hande Sciences","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Partnership","leadProduct":"QN-302","moa":"G4-quadruplex transcription","graph1":"Oncology","graph2":"IND Enabling","graph3":"Qualigen Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Qualigen Therapeutics \/ Hande Sciences","highestDevelopmentStatusID":"5","companyTruncated":"Qualigen Therapeutics \/ Hande Sciences"},{"orgOrder":0,"company":"Qualigen Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"QN-302","moa":"G4-quadruplex transcription","graph1":"Oncology","graph2":"IND Enabling","graph3":"Qualigen Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Qualigen Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Qualigen Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Qualigen Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"QN-302","moa":"G4-quadruplex transcription","graph1":"Oncology","graph2":"IND Enabling","graph3":"Qualigen Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Qualigen Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Qualigen Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Qualigen Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"QN-302","moa":"G4-quadruplex transcription","graph1":"Oncology","graph2":"IND Enabling","graph3":"Qualigen Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Qualigen Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Qualigen Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Qualigen Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"QN-302","moa":"G4-quadruplex transcription","graph1":"Oncology","graph2":"IND Enabling","graph3":"Qualigen Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Qualigen Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Qualigen Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Qualigen Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"QN-302","moa":"G4-quadruplex transcription","graph1":"Oncology","graph2":"IND Enabling","graph3":"Qualigen Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Qualigen Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Qualigen Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Qualigen Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"QN-302","moa":"G4-quadruplex transcription","graph1":"Oncology","graph2":"IND Enabling","graph3":"Qualigen Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Qualigen Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Qualigen Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Qualigen Therapeutics","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"QN-302","moa":"G4-quadruplex transcription","graph1":"Oncology","graph2":"IND Enabling","graph3":"Qualigen Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Qualigen Therapeutics \/ Merck & Co","highestDevelopmentStatusID":"5","companyTruncated":"Qualigen Therapeutics \/ Merck & Co"},{"orgOrder":0,"company":"Qualigen Therapeutics","sponsor":"University College London","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"QN-302","moa":"G4-quadruplex transcription","graph1":"Oncology","graph2":"IND Enabling","graph3":"Qualigen Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Qualigen Therapeutics \/ University College London","highestDevelopmentStatusID":"5","companyTruncated":"Qualigen Therapeutics \/ University College London"},{"orgOrder":0,"company":"Sofie Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"68-Ga FAPI-46","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"Sofie Biosciences","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sofie Biosciences \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Sofie Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"InProTher","sponsor":"European Innovation Council","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"DENMARK","productType":"Vaccine","year":"2023","type":"Financing","leadProduct":"IPT001","moa":"HERVs","graph1":"Oncology","graph2":"IND Enabling","graph3":"InProTher","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"InProTher \/ European Innovation Council","highestDevelopmentStatusID":"5","companyTruncated":"InProTher \/ European Innovation Council"},{"orgOrder":0,"company":"GEDiCube","sponsor":"Renovaro Biosciences","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"NETHERLANDS","productType":"Vaccine","year":"2023","type":"Merger","leadProduct":"Dendritic Cell Vaccine","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"GEDiCube","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"GEDiCube \/ Renovaro Biosciences","highestDevelopmentStatusID":"5","companyTruncated":"GEDiCube \/ Renovaro Biosciences"},{"orgOrder":0,"company":"Xenetic Biosciences","sponsor":"PeriNess","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Enzyme","year":"2024","type":"Agreement","leadProduct":"XBIO-015","moa":"NET","graph1":"Oncology","graph2":"IND Enabling","graph3":"Xenetic Biosciences","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Xenetic Biosciences \/ PeriNess","highestDevelopmentStatusID":"5","companyTruncated":"Xenetic Biosciences \/ PeriNess"},{"orgOrder":0,"company":"Cellectar","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"CLR 121225","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"Cellectar","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Cellectar \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Cellectar \/ Inapplicable"},{"orgOrder":0,"company":"CD (Suzhou) Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Large Molecule","year":"2024","type":"Inapplicable","leadProduct":"CD-001","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"CD (Suzhou) Biopharma","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"CD (Suzhou) Biopharma \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"CD (Suzhou) Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"Radiopharm Theranostics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"RAD204","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"Radiopharm Theranostics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Radiopharm Theranostics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Radiopharm Theranostics \/ Inapplicable"},{"orgOrder":0,"company":"OnKure Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"OKI-219","moa":"PI3K-alpha-H1047R","graph1":"Oncology","graph2":"IND Enabling","graph3":"OnKure Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"OnKure Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"OnKure Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"JW Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Relmacabtagene Autoleucel","moa":"CD19","graph1":"Oncology","graph2":"IND Enabling","graph3":"JW Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"JW Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"JW Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Curia","sponsor":"BryoLogyx Inc","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Collaboration","leadProduct":"Bryostatin-1","moa":"PKC","graph1":"Oncology","graph2":"IND Enabling","graph3":"Curia","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Curia \/ BryoLogyx Inc","highestDevelopmentStatusID":"5","companyTruncated":"Curia \/ BryoLogyx Inc"},{"orgOrder":0,"company":"Neurotrope","sponsor":"BryoLogyx Inc","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Agreement","leadProduct":"Bryostatin-1","moa":"PKC","graph1":"Oncology","graph2":"IND Enabling","graph3":"Neurotrope","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Neurotrope \/ BryoLogyx Inc","highestDevelopmentStatusID":"5","companyTruncated":"Neurotrope \/ BryoLogyx Inc"},{"orgOrder":0,"company":"Cellenkos","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"CK0804","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"Cellenkos","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Cellenkos \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Cellenkos \/ Inapplicable"},{"orgOrder":0,"company":"National Cancer Institute","sponsor":"Propella Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Partnership","leadProduct":"Abiraterone Decanoate","moa":"CYP17","graph1":"Oncology","graph2":"IND Enabling","graph3":"National Cancer Institute","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"National Cancer Institute \/ Propella Therapeutics","highestDevelopmentStatusID":"5","companyTruncated":"National Cancer Institute \/ Propella Therapeutics"},{"orgOrder":0,"company":"Columbia University","sponsor":"Ayala Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2021","type":"Agreement","leadProduct":"ADXS-504","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"Columbia University","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Columbia University \/ Ayala Pharmaceuticals","highestDevelopmentStatusID":"5","companyTruncated":"Columbia University \/ Ayala Pharmaceuticals"},{"orgOrder":0,"company":"Jemincare","sponsor":"Genentech","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2022","type":"Licensing Agreement","leadProduct":"JMKX002992","moa":"Androgen receptor","graph1":"Oncology","graph2":"IND Enabling","graph3":"Jemincare","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Jemincare \/ Genentech","highestDevelopmentStatusID":"5","companyTruncated":"Jemincare \/ Genentech"},{"orgOrder":0,"company":"Ionetix","sponsor":"Precision Molecular","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Agreement","leadProduct":"PMI21","moa":"PSMA","graph1":"Oncology","graph2":"IND Enabling","graph3":"Ionetix","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ionetix \/ Precision Molecular","highestDevelopmentStatusID":"5","companyTruncated":"Ionetix \/ Precision Molecular"},{"orgOrder":0,"company":"Mateon Therapeutics","sponsor":"Oceanpine Capital","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Series A Financing","leadProduct":"TT-702","moa":"A2BR","graph1":"Oncology","graph2":"IND Enabling","graph3":"Mateon Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Mateon Therapeutics \/ Oceanpine Capital","highestDevelopmentStatusID":"5","companyTruncated":"Mateon Therapeutics \/ Oceanpine Capital"},{"orgOrder":0,"company":"Teon Therapeutics","sponsor":"Cancer Research","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Collaboration","leadProduct":"TT-702","moa":"A2BR","graph1":"Oncology","graph2":"IND Enabling","graph3":"Teon Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Teon Therapeutics \/ Cancer Research","highestDevelopmentStatusID":"5","companyTruncated":"Teon Therapeutics \/ Cancer Research"},{"orgOrder":0,"company":"Teon Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"TT-702","moa":"A2BR","graph1":"Oncology","graph2":"IND Enabling","graph3":"Teon Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Teon Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Teon Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"BriaCell Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"Bria-Pros+","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"BriaCell Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"BriaCell Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"BriaCell Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"BriaPro Therapeutics","sponsor":"BriaCell Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CANADA","productType":"Cell and Gene therapy","year":"2023","type":"Demerger","leadProduct":"Bria-TILsRx","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"BriaPro Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"BriaPro Therapeutics \/ BriaCell Therapeutics","highestDevelopmentStatusID":"5","companyTruncated":"BriaPro Therapeutics \/ BriaCell Therapeutics"},{"orgOrder":0,"company":"BriaPro Therapeutics","sponsor":"BriaCell Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CANADA","productType":"Cell and Gene therapy","year":"2023","type":"Demerger","leadProduct":"Bria-TILsRx","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"BriaPro Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"BriaPro Therapeutics \/ BriaCell Therapeutics","highestDevelopmentStatusID":"5","companyTruncated":"BriaPro Therapeutics \/ BriaCell Therapeutics"},{"orgOrder":0,"company":"Hervolution Therapeutics","sponsor":"Serum Institute of India","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"DENMARK","productType":"Vaccine","year":"2024","type":"Series A Financing","leadProduct":"IPT-001","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"Hervolution Therapeutics","amount2":0.01,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0.01,"dosageForm":"Undisclosed","sponsorNew":"Hervolution Therapeutics \/ Serum Institute of India","highestDevelopmentStatusID":"5","companyTruncated":"Hervolution Therapeutics \/ Serum Institute of India"},{"orgOrder":0,"company":"Cancer Targeted Technology","sponsor":"The Division of Cancer Treatment and Diagnosis","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Funding","leadProduct":"CTT2274","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"Cancer Targeted Technology","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Cancer Targeted Technology \/ The Division of Cancer Treatment and Diagnosis","highestDevelopmentStatusID":"5","companyTruncated":"Cancer Targeted Technology \/ The Division of Cancer Treatment and Diagnosis"},{"orgOrder":0,"company":"Clarity Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Radiolabelled Compounds","year":"2022","type":"Inapplicable","leadProduct":"Sar-Bombesin","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"Clarity Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Clarity Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Clarity Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Hookipa Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"HB-300","moa":"PAP\/PSA","graph1":"Oncology","graph2":"IND Enabling","graph3":"Hookipa Pharma","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hookipa Pharma \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Hookipa Pharma \/ Inapplicable"},{"orgOrder":0,"company":"HDT Biotech","sponsor":"BARDA","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2024","type":"Partnership","leadProduct":"HDT-521","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"HDT Biotech","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"HDT Biotech \/ BARDA","highestDevelopmentStatusID":"5","companyTruncated":"HDT Biotech \/ BARDA"},{"orgOrder":0,"company":"Lava Therapeutics","sponsor":"Merck & Co","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"NETHERLANDS","productType":"Antibody","year":"2024","type":"Collaboration","leadProduct":"LAVA-1207","moa":"||Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"Lava Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Lava Therapeutics \/ Merck & Co","highestDevelopmentStatusID":"5","companyTruncated":"Lava Therapeutics \/ Merck & Co"},{"orgOrder":0,"company":"Pasithea Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"PAS-004","moa":"MEK1\/2 receptor","graph1":"Oncology","graph2":"IND Enabling","graph3":"Pasithea Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pasithea Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Pasithea Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Pasithea Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"PAS-004","moa":"MEK1\/2 receptor","graph1":"Oncology","graph2":"IND Enabling","graph3":"Pasithea Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pasithea Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Pasithea Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"280Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"YL-17231","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"280Bio","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"280Bio \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"280Bio \/ Inapplicable"},{"orgOrder":0,"company":"GT Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"GTB-3650","moa":"CD33","graph1":"Oncology","graph2":"IND Enabling","graph3":"GT Biopharma","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"GT Biopharma \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"GT Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"Interius BioTherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"INT2104","moa":"CD7","graph1":"Oncology","graph2":"IND Enabling","graph3":"Interius BioTherapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Interius BioTherapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Interius BioTherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Auron Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"AUTX-703","moa":"KAT2A\/B","graph1":"Oncology","graph2":"IND Enabling","graph3":"Auron Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Auron Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Auron Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Replay Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"Decitabine","moa":"||Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"Replay Bio","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Replay Bio \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Replay Bio \/ Inapplicable"},{"orgOrder":0,"company":"Hemogenyx Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"HEMO-CAR-T","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"Hemogenyx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hemogenyx Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Hemogenyx Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Kurome Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"KME-0584","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"Kurome Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Kurome Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Kurome Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"BlueSphere Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"BSB-1001","moa":"HA-1 receptor","graph1":"Oncology","graph2":"IND Enabling","graph3":"BlueSphere Bio","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"BlueSphere Bio \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"BlueSphere Bio \/ Inapplicable"},{"orgOrder":0,"company":"BlueSphere Bio","sponsor":"NMDP BioTherapies","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Partnership","leadProduct":"BSB-1001","moa":"HA-1 receptor","graph1":"Oncology","graph2":"IND Enabling","graph3":"BlueSphere Bio","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"BlueSphere Bio \/ NMDP BioTherapies","highestDevelopmentStatusID":"5","companyTruncated":"BlueSphere Bio \/ NMDP BioTherapies"},{"orgOrder":0,"company":"Hemogenyx Pharmaceuticals","sponsor":"Prevail Partners","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2024","type":"Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"Hemogenyx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hemogenyx Pharmaceuticals \/ Prevail Partners","highestDevelopmentStatusID":"5","companyTruncated":"Hemogenyx Pharmaceuticals \/ Prevail Partners"},{"orgOrder":0,"company":"LTZ Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2025","type":"Inapplicable","leadProduct":"LTZ-301","moa":"CD79b\/B-cell","graph1":"Oncology","graph2":"IND Enabling","graph3":"LTZ Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"LTZ Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"LTZ Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"LTZ Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2025","type":"Inapplicable","leadProduct":"LTZ-301","moa":"CD79b\/B-cell","graph1":"Oncology","graph2":"IND Enabling","graph3":"LTZ Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"LTZ Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"LTZ Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Innovent Biologics","sponsor":"IASO Bio","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Cell and Gene therapy","year":"2024","type":"Licensing Agreement","leadProduct":"Equecabtagene Autoleucel","moa":"BCMA receptor","graph1":"Oncology","graph2":"IND Enabling","graph3":"Innovent Biologics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Innovent Biologics \/ IASO Bio","highestDevelopmentStatusID":"5","companyTruncated":"Innovent Biologics \/ IASO Bio"},{"orgOrder":0,"company":"Cullinan Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"CLN-619","moa":"MICA\/MICB protein","graph1":"Oncology","graph2":"IND Enabling","graph3":"Cullinan Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Cullinan Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Cullinan Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Kangpu Biopharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GREECE","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"KPG-818","moa":"CRL4-CRBN","graph1":"Oncology","graph2":"IND Enabling","graph3":"Kangpu Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Kangpu Biopharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Kangpu Biopharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"IASO Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"RD118","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"IASO Bio","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"IASO Bio \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"IASO Bio \/ Inapplicable"},{"orgOrder":0,"company":"Senhwa Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"TAIWAN","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Silmitasertib","moa":"CK2-alpha","graph1":"Oncology","graph2":"IND Enabling","graph3":"Senhwa Biosciences","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Senhwa Biosciences \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Senhwa Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Oxular","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"OXU-003","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"Oxular","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Oxular \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Oxular \/ Inapplicable"},{"orgOrder":0,"company":"BioRay Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody-drug Conjugate","year":"2025","type":"Inapplicable","leadProduct":"BR111","moa":"ROR1 receptor","graph1":"Oncology","graph2":"IND Enabling","graph3":"BioRay Pharmaceutical","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"BioRay Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"BioRay Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Beijing Avistone Pharmaceuticals Biotechnology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"ANS03","moa":"TYK","graph1":"Oncology","graph2":"IND Enabling","graph3":"Beijing Avistone Pharmaceuticals Biotechnology","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Beijing Avistone Pharmaceuticals Biotechnology \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Beijing Avistone Pharmaceuticals Biotechnology \/ Inapplicable"},{"orgOrder":0,"company":"C4 Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"CFT8634","moa":"Bromodomain-9","graph1":"Oncology","graph2":"IND Enabling","graph3":"C4 Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"C4 Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"C4 Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Adcendo","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"DENMARK","productType":"Other Large Molecule","year":"2024","type":"Inapplicable","leadProduct":"ADCE-D01","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"Adcendo","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Adcendo \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Adcendo \/ Inapplicable"},{"orgOrder":0,"company":"Replay Bio","sponsor":"The University of Texas MD Anderson Cancer Center","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"Replay Bio","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Replay Bio \/ The University of Texas MD Anderson Cancer Center","highestDevelopmentStatusID":"5","companyTruncated":"Replay Bio \/ The University of Texas MD Anderson Cancer Center"},{"orgOrder":0,"company":"AiViva Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Axitinib","moa":"VEGF receptor","graph1":"Oncology","graph2":"IND Enabling","graph3":"AiViva Biopharma","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"AiViva Biopharma \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"AiViva Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"Oncorus","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Microorganism","year":"2022","type":"Inapplicable","leadProduct":"ONCR-788","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"Oncorus","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Oncorus \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Oncorus \/ Inapplicable"},{"orgOrder":0,"company":"Auron Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"AUTX-703","moa":"KAT2A\/B","graph1":"Oncology","graph2":"IND Enabling","graph3":"Auron Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Auron Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Auron Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Auron Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"AUTX-703","moa":"KAT2A\/B","graph1":"Oncology","graph2":"IND Enabling","graph3":"Auron Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Auron Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Auron Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Abdera Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Radiolabelled Compounds","year":"2024","type":"Inapplicable","leadProduct":"ABD-147","moa":"Alpha-radiation","graph1":"Oncology","graph2":"IND Enabling","graph3":"Abdera Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Abdera Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Abdera Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Abdera Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Radiolabelled Compounds","year":"2024","type":"Inapplicable","leadProduct":"ABD-147","moa":"Alpha-radiation","graph1":"Oncology","graph2":"IND Enabling","graph3":"Abdera Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Abdera Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Abdera Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Abdera Therapeutics","sponsor":"Versant Ventures","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Radiolabelled Compounds","year":"2023","type":"Financing","leadProduct":"ABD-147","moa":"Alpha-radiation","graph1":"Oncology","graph2":"IND Enabling","graph3":"Abdera Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Abdera Therapeutics \/ Versant Ventures","highestDevelopmentStatusID":"5","companyTruncated":"Abdera Therapeutics \/ Versant Ventures"},{"orgOrder":0,"company":"OncoBay Clinical","sponsor":"Hillstream BioPharma","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Agreement","leadProduct":"Salinomycin","moa":"Ferroptosis","graph1":"Oncology","graph2":"IND Enabling","graph3":"OncoBay Clinical","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"OncoBay Clinical \/ Hillstream BioPharma","highestDevelopmentStatusID":"5","companyTruncated":"OncoBay Clinical \/ Hillstream BioPharma"},{"orgOrder":0,"company":"Algernon Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Ifenprodil Tartrate","moa":"||NMDA subunit-2B receptor","graph1":"Oncology","graph2":"IND Enabling","graph3":"Algernon Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Algernon Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Algernon Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Hillstream BioPharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Salinomycin","moa":"Ferroptosis","graph1":"Oncology","graph2":"IND Enabling","graph3":"Hillstream BioPharma","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hillstream BioPharma \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Hillstream BioPharma \/ Inapplicable"},{"orgOrder":0,"company":"Hillstream BioPharma","sponsor":"Thinkequity","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Public Offering","leadProduct":"Salinomycin","moa":"Ferroptosis","graph1":"Oncology","graph2":"IND Enabling","graph3":"Hillstream BioPharma","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hillstream BioPharma \/ Thinkequity","highestDevelopmentStatusID":"5","companyTruncated":"Hillstream BioPharma \/ Thinkequity"},{"orgOrder":0,"company":"Hillstream BioPharma","sponsor":"Thinkequity","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Public Offering","leadProduct":"Salinomycin","moa":"Ferroptosis","graph1":"Oncology","graph2":"IND Enabling","graph3":"Hillstream BioPharma","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hillstream BioPharma \/ Thinkequity","highestDevelopmentStatusID":"5","companyTruncated":"Hillstream BioPharma \/ Thinkequity"},{"orgOrder":0,"company":"Hillstream BioPharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Salinomycin","moa":"Ferroptosis","graph1":"Oncology","graph2":"IND Enabling","graph3":"Hillstream BioPharma","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hillstream BioPharma \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Hillstream BioPharma \/ Inapplicable"},{"orgOrder":0,"company":"NeoImmuneTech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Efineptakin Alpha","moa":"||IL-7 receptor","graph1":"Oncology","graph2":"IND Enabling","graph3":"NeoImmuneTech","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"NeoImmuneTech \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"NeoImmuneTech \/ Inapplicable"},{"orgOrder":0,"company":"Immunome","sponsor":"Enavate Sciences","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Private Placement","leadProduct":"IMM-ONC-01","moa":"IL-38 receptor","graph1":"Oncology","graph2":"IND Enabling","graph3":"Immunome","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Immunome \/ Enavate Sciences","highestDevelopmentStatusID":"5","companyTruncated":"Immunome \/ Enavate Sciences"},{"orgOrder":0,"company":"Immunome","sponsor":"Fox Chase Cancer Center","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"IMM-ONC-01","moa":"IL-38 receptor","graph1":"Oncology","graph2":"IND Enabling","graph3":"Immunome","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Immunome \/ Fox Chase Cancer Center","highestDevelopmentStatusID":"5","companyTruncated":"Immunome \/ Fox Chase Cancer Center"},{"orgOrder":0,"company":"Nusano","sponsor":"Starget Pharma","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Peptide","year":"2024","type":"Agreement","leadProduct":"DOTA-PTR-58","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"Nusano","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Nusano \/ Starget Pharma","highestDevelopmentStatusID":"5","companyTruncated":"Nusano \/ Starget Pharma"},{"orgOrder":0,"company":"Tango Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"TNG260","moa":"CoREST-HDAC","graph1":"Oncology","graph2":"IND Enabling","graph3":"Tango Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Tango Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Tango Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Alligator Bioscience","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"HLX22","moa":"||HER2","graph1":"Oncology","graph2":"IND Enabling","graph3":"Alligator Bioscience","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Alligator Bioscience \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Alligator Bioscience \/ Inapplicable"},{"orgOrder":0,"company":"Medigene","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"MDG1015","moa":"NY-ESO-1\/LAGE-1a","graph1":"Oncology","graph2":"IND Enabling","graph3":"Medigene","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Medigene \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Medigene \/ Inapplicable"},{"orgOrder":0,"company":"Medigene","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"MDG1015","moa":"NY-ESO-1\/LAGE-1a","graph1":"Oncology","graph2":"IND Enabling","graph3":"Medigene","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Medigene \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Medigene \/ Inapplicable"},{"orgOrder":0,"company":"CytoImmune Therapeutics","sponsor":"City of Hope","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Licensing Agreement","leadProduct":"CYTO NK-203","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"CytoImmune Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"CytoImmune Therapeutics \/ City of Hope","highestDevelopmentStatusID":"5","companyTruncated":"CytoImmune Therapeutics \/ City of Hope"},{"orgOrder":0,"company":"Tempus","sponsor":"Avacta Group","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Peptide","year":"2024","type":"Collaboration","leadProduct":"AVA6103","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"Tempus","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Tempus \/ Avacta Group","highestDevelopmentStatusID":"5","companyTruncated":"Tempus \/ Avacta Group"},{"orgOrder":0,"company":"Qure Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Q-1802","moa":"PD-L1","graph1":"Oncology","graph2":"IND Enabling","graph3":"Qure Biotech","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Qure Biotech \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Qure Biotech \/ Inapplicable"},{"orgOrder":0,"company":"Shandong Boan Biotechnology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"BA1105","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"Shandong Boan Biotechnology","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Shandong Boan Biotechnology \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Shandong Boan Biotechnology \/ Inapplicable"},{"orgOrder":0,"company":"Avacta Group","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Peptide","year":"2024","type":"Inapplicable","leadProduct":"AVA6103","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"Avacta Group","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Avacta Group \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Avacta Group \/ Inapplicable"},{"orgOrder":0,"company":"NeoImmuneTech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Efineptakin Alpha","moa":"||IL-7 receptor","graph1":"Oncology","graph2":"IND Enabling","graph3":"NeoImmuneTech","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"NeoImmuneTech \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"NeoImmuneTech \/ Inapplicable"},{"orgOrder":0,"company":"GX Acquisition","sponsor":"Celularity","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Merger","leadProduct":"CYNK-101","moa":"||CD-38","graph1":"Oncology","graph2":"IND Enabling","graph3":"GX Acquisition","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"GX Acquisition \/ Celularity","highestDevelopmentStatusID":"5","companyTruncated":"GX Acquisition \/ Celularity"},{"orgOrder":0,"company":"Molecular Targeting Technologies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"177-Lu DOTA-EB-TATE","moa":"SST2 receptor","graph1":"Oncology","graph2":"IND Enabling","graph3":"Molecular Targeting Technologies","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Molecular Targeting Technologies \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Molecular Targeting Technologies \/ Inapplicable"},{"orgOrder":0,"company":"Puerto Rico Science Technology and Research Trust","sponsor":"Revive Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"PUERTO RICO","productType":"Undisclosed","year":"2021","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"Puerto Rico Science Technology and Research Trust","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Puerto Rico Science Technology and Research Trust \/ Revive Therapeutics","highestDevelopmentStatusID":"5","companyTruncated":"Puerto Rico Science Technology and Research Trust \/ Revive Therapeutics"},{"orgOrder":0,"company":"National Cancer Institute","sponsor":"Navrogen","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2022","type":"Agreement","leadProduct":"NAV-001","moa":"MSLN","graph1":"Oncology","graph2":"IND Enabling","graph3":"National Cancer Institute","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"National Cancer Institute \/ Navrogen","highestDevelopmentStatusID":"5","companyTruncated":"National Cancer Institute \/ Navrogen"},{"orgOrder":0,"company":"Elpis Biopharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Large Molecule","year":"2022","type":"Inapplicable","leadProduct":"EPIM-001","moa":"||IL-2-beta-receptor","graph1":"Oncology","graph2":"IND Enabling","graph3":"Elpis Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Elpis Biopharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Elpis Biopharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Hillstream BioPharma","sponsor":"Dana-Farber Cancer Institute","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Agreement","leadProduct":"Salinomycin","moa":"Ferroptosis","graph1":"Oncology","graph2":"IND Enabling","graph3":"Hillstream BioPharma","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hillstream BioPharma \/ Dana-Farber Cancer Institute","highestDevelopmentStatusID":"5","companyTruncated":"Hillstream BioPharma \/ Dana-Farber Cancer Institute"},{"orgOrder":0,"company":"Monopar Therapeutics","sponsor":"North Star Processing, LLC.","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"MNPR-101-Zr","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"Monopar Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Monopar Therapeutics \/ North Star Processing, LLC.","highestDevelopmentStatusID":"5","companyTruncated":"Monopar Therapeutics \/ North Star Processing, LLC."},{"orgOrder":0,"company":"Rondo Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2025","type":"Inapplicable","leadProduct":"RNDO-564","moa":"CD28\/Nectin-4","graph1":"Oncology","graph2":"IND Enabling","graph3":"Rondo Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Rondo Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Rondo Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Flare Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"3-(5,7-difluoro-4-oxo-1H-quinolin-2-yl)-4-methylsulfonylbenzonitrile","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"Flare Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Flare Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Flare Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"UroGen Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Zalifrelimab","moa":"Toll-like-7 receptor","graph1":"Oncology","graph2":"IND Enabling","graph3":"UroGen Pharma","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"UroGen Pharma \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"UroGen Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Caris Life Sciences","sponsor":"Flare Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Partnership","leadProduct":"3-(5,7-difluoro-4-oxo-1H-quinolin-2-yl)-4-methylsulfonylbenzonitrile","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"Caris Life Sciences","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Caris Life Sciences \/ Flare Therapeutics","highestDevelopmentStatusID":"5","companyTruncated":"Caris Life Sciences \/ Flare Therapeutics"},{"orgOrder":0,"company":"Nuvectis Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"NXP900","moa":"YES1\/Src-family kinase","graph1":"Oncology","graph2":"IND Enabling","graph3":"Nuvectis Pharma","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Nuvectis Pharma \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Nuvectis Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Roca Therapeutics","sponsor":"3B Future Health Fund II","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"FRANCE","productType":"Other Small Molecule","year":"2022","type":"Financing","leadProduct":"RCT001","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"Roca Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Roca Therapeutics \/ 3B Future Health Fund II","highestDevelopmentStatusID":"5","companyTruncated":"Roca Therapeutics \/ 3B Future Health Fund II"},{"orgOrder":0,"company":"Hillstream BioPharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Salinomycin","moa":"Ferroptosis","graph1":"Oncology","graph2":"IND Enabling","graph3":"Hillstream BioPharma","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hillstream BioPharma \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Hillstream BioPharma \/ Inapplicable"},{"orgOrder":0,"company":"TigaTx","sponsor":"Epsilogen","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2025","type":"Acquisition","leadProduct":"EPS 401","moa":"EGFR","graph1":"Oncology","graph2":"IND Enabling","graph3":"TigaTx","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"TigaTx \/ Epsilogen","highestDevelopmentStatusID":"5","companyTruncated":"TigaTx \/ Epsilogen"},{"orgOrder":0,"company":"Adaptin Bio","sponsor":"Laidlaw & Company","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2025","type":"Private Placement","leadProduct":"APTN-101","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"Adaptin Bio","amount2":0.01,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0.01,"dosageForm":"Undisclosed","sponsorNew":"Adaptin Bio \/ Laidlaw & Company","highestDevelopmentStatusID":"5","companyTruncated":"Adaptin Bio \/ Laidlaw & Company"},{"orgOrder":0,"company":"ALX Oncology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2025","type":"Inapplicable","leadProduct":"ALX2004","moa":"EGFR","graph1":"Oncology","graph2":"IND Enabling","graph3":"ALX Oncology","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ALX Oncology \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"ALX Oncology \/ Inapplicable"},{"orgOrder":0,"company":"PDS Biotechnology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2025","type":"Inapplicable","leadProduct":"PDS01ADC","moa":"||MUC1","graph1":"Oncology","graph2":"IND Enabling","graph3":"PDS Biotechnology","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"PDS Biotechnology \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"PDS Biotechnology \/ Inapplicable"},{"orgOrder":0,"company":"Radiance Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2025","type":"Inapplicable","leadProduct":"RB-164","moa":"ROR1","graph1":"Oncology","graph2":"IND Enabling","graph3":"Radiance Biopharma","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Radiance Biopharma \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Radiance Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"Sun Pharma Advanced Research Company","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"INDIA","productType":"Antibody-drug Conjugate","year":"2025","type":"Inapplicable","leadProduct":"SBO-154","moa":"MUC1","graph1":"Oncology","graph2":"IND Enabling","graph3":"Sun Pharma Advanced Research Company","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sun Pharma Advanced Research Company \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Sun Pharma Advanced Research Company \/ Inapplicable"},{"orgOrder":0,"company":"Anocca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Cell and Gene therapy","year":"2025","type":"Inapplicable","leadProduct":"ANOC-001","moa":"KRAS G12V","graph1":"Oncology","graph2":"IND Enabling","graph3":"Anocca","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Anocca \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Anocca \/ Inapplicable"},{"orgOrder":0,"company":"Calidi Biotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2025","type":"Inapplicable","leadProduct":"CLD-201","moa":"Tumor growth","graph1":"Oncology","graph2":"IND Enabling","graph3":"Calidi Biotherapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Calidi Biotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Calidi Biotherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Ensem Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"ETX\u2013636","moa":"PI3K-alpha","graph1":"Oncology","graph2":"IND Enabling","graph3":"Ensem Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Ensem Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Ensem Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Avidicure","sponsor":"EQT Life Sciences","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"NETHERLANDS","productType":"Antibody","year":"2025","type":"Financing","leadProduct":"AVC-S-101","moa":"Trop2","graph1":"Oncology","graph2":"IND Enabling","graph3":"Avidicure","amount2":0.050000000000000003,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0.050000000000000003,"dosageForm":"Undisclosed","sponsorNew":"Avidicure \/ EQT Life Sciences","highestDevelopmentStatusID":"5","companyTruncated":"Avidicure \/ EQT Life Sciences"},{"orgOrder":0,"company":"Ona Therapeutics","sponsor":"Reveal Genomics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SPAIN","productType":"Antibody-drug Conjugate","year":"2025","type":"Collaboration","leadProduct":"ONA-255","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"Ona Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ona Therapeutics \/ Reveal Genomics","highestDevelopmentStatusID":"5","companyTruncated":"Ona Therapeutics \/ Reveal Genomics"},{"orgOrder":0,"company":"CureVac","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Oligonucleotide","year":"2025","type":"Inapplicable","leadProduct":"CVHNLC","moa":"||Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"CureVac","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"CureVac \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"CureVac \/ Inapplicable"},{"orgOrder":0,"company":"Onward Therapeutics","sponsor":"EMERCell","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Cell and Gene therapy","year":"2025","type":"Inapplicable","leadProduct":"OT-C001","moa":"||Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"Onward Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Onward Therapeutics \/ Emercell","highestDevelopmentStatusID":"5","companyTruncated":"Onward Therapeutics \/ Emercell"},{"orgOrder":0,"company":"Tagworks Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"NETHERLANDS","productType":"Antibody-drug Conjugate","year":"2025","type":"Inapplicable","leadProduct":"TGW101","moa":"TAG-72","graph1":"Oncology","graph2":"IND Enabling","graph3":"Tagworks Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Tagworks Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Tagworks Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Connoya Biomedical Technology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody-drug Conjugate","year":"2025","type":"Inapplicable","leadProduct":"CM518D1","moa":"CDH17","graph1":"Oncology","graph2":"IND Enabling","graph3":"Connoya Biomedical Technology","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Connoya Biomedical Technology \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Connoya Biomedical Technology \/ Inapplicable"},{"orgOrder":0,"company":"Nutshell Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"NTS071","moa":"p53 Y220C","graph1":"Oncology","graph2":"IND Enabling","graph3":"Nutshell Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Nutshell Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Nutshell Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"OBI Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"TAIWAN","productType":"Antibody-drug Conjugate","year":"2025","type":"Inapplicable","leadProduct":"OBI-902","moa":"Trop2","graph1":"Oncology","graph2":"IND Enabling","graph3":"OBI Pharma","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"OBI Pharma \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"OBI Pharma \/ Inapplicable"},{"orgOrder":0,"company":"TFS International AB","sponsor":"Oncomatryx","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2025","type":"Collaboration","leadProduct":"OMTX705","moa":"FAP-alpha\/Tubulin","graph1":"Oncology","graph2":"IND Enabling","graph3":"TFS International AB","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"TFS International AB \/ Oncomatryx","highestDevelopmentStatusID":"5","companyTruncated":"TFS International AB \/ Oncomatryx"},{"orgOrder":0,"company":"Erasca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"ERAS-0015","moa":"RAS","graph1":"Oncology","graph2":"IND Enabling","graph3":"Erasca","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Erasca \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Erasca \/ Inapplicable"},{"orgOrder":0,"company":"UTR Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Oligonucleotide","year":"2025","type":"Inapplicable","leadProduct":"UTRxM1-18","moa":"c-Myc","graph1":"Oncology","graph2":"IND Enabling","graph3":"UTR Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"UTR Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"UTR Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Hoth Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2025","type":"Inapplicable","leadProduct":"HT-KIT","moa":"c-KIT receptor","graph1":"Oncology","graph2":"IND Enabling","graph3":"Hoth Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hoth Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Hoth Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Lantern Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2025","type":"Inapplicable","leadProduct":"LP-184","moa":"||PTGR1","graph1":"Oncology","graph2":"IND Enabling","graph3":"Lantern Pharma","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Lantern Pharma \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Lantern Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Allorion Therapeutics","sponsor":"Avenzo Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Licensing Agreement","leadProduct":"AVZO-023","moa":"CDK4","graph1":"Oncology","graph2":"IND Enabling","graph3":"Allorion Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Allorion Therapeutics \/ Avenzo Therapeutics","highestDevelopmentStatusID":"5","companyTruncated":"Allorion Therapeutics \/ Avenzo Therapeutics"},{"orgOrder":0,"company":"Avenzo Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2025","type":"Inapplicable","leadProduct":"AVZO-1418","moa":"EGFR\/HER3","graph1":"Oncology","graph2":"IND Enabling","graph3":"Avenzo Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Avenzo Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Avenzo Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Medicovestor","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2025","type":"Inapplicable","leadProduct":"N-Cystaminyl Biguanide","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"Medicovestor","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Medicovestor \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Medicovestor \/ Inapplicable"},{"orgOrder":0,"company":"Myosin Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"MT-125","moa":"NMII","graph1":"Oncology","graph2":"IND Enabling","graph3":"Myosin Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Myosin Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Myosin Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Cellectar","sponsor":"Ladenburg Thalmann & Co","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Radiolabelled Compounds","year":"2025","type":"Public Offering","leadProduct":"CLR 125","moa":"Ionising radiation","graph1":"Oncology","graph2":"IND Enabling","graph3":"Cellectar","amount2":0.01,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0.01,"dosageForm":"Undisclosed","sponsorNew":"Cellectar \/ Ladenburg Thalmann & Co","highestDevelopmentStatusID":"5","companyTruncated":"Cellectar \/ Ladenburg Thalmann & Co"},{"orgOrder":0,"company":"Cellectar","sponsor":"Ladenburg Thalmann & Co","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Radiolabelled Compounds","year":"2025","type":"Public Offering","leadProduct":"CLR 125","moa":"Ionising radiation","graph1":"Oncology","graph2":"IND Enabling","graph3":"Cellectar","amount2":0.01,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0.01,"dosageForm":"Undisclosed","sponsorNew":"Cellectar \/ Ladenburg Thalmann & Co","highestDevelopmentStatusID":"5","companyTruncated":"Cellectar \/ Ladenburg Thalmann & Co"},{"orgOrder":0,"company":"InnoCare Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody-drug Conjugate","year":"2025","type":"Inapplicable","leadProduct":"ICP-B794","moa":"B7-H3","graph1":"Oncology","graph2":"IND Enabling","graph3":"InnoCare Pharma","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"InnoCare Pharma \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"InnoCare Pharma \/ Inapplicable"}]

    Find FDA Investigational New Drug (IND) Submissions for Oncology in KOREA, REPUBLIC OF

    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Myosin Therapeutics

                            U.S.A arrow
                            IFT FIRST
                            Not Confirmed

                            Myosin Therapeutics

                            U.S.A arrow
                            IFT FIRST
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : MT-125

                            Therapeutic Area : Oncology

                            Study Phase : IND Enabling

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Myosin Receives FDA Clearance to Initiate First-in-Human Trial of MT-125 in Glioblastoma

                            Details : MT-125 is a selective inhibitor of non-muscle myosin II (NMII), designed to disrupt critical mechanisms of glioblastoma progression.

                            Product Name : MT-125

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            June 09, 2025

                            Lead Product(s) : MT-125

                            Therapeutic Area : Oncology

                            Highest Development Status : IND Enabling

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Hoth Therapeutics

                            U.S.A arrow
                            IFT FIRST
                            Not Confirmed

                            Hoth Therapeutics

                            U.S.A arrow
                            IFT FIRST
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : HT-KIT

                            Therapeutic Area : Oncology

                            Study Phase : IND Enabling

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Hoth Reports Strong Preclinical Data for HT-KIT in Rare KIT-Driven Cancers

                            Details : HT-KIT is engineered to selectively bind to mutant KIT mRNA transcripts and block their translation, thereby preventing the production of the KIT protein.

                            Product Name : HT-KIT

                            Product Type : Cell and Gene therapy

                            Upfront Cash : Inapplicable

                            May 12, 2025

                            Lead Product(s) : HT-KIT

                            Therapeutic Area : Oncology

                            Highest Development Status : IND Enabling

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Lantern Pharma

                            U.S.A arrow
                            IFT FIRST
                            Not Confirmed

                            Lantern Pharma

                            U.S.A arrow
                            IFT FIRST
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : LP-184,Nivolumab,Ipilimumab

                            Therapeutic Area : Oncology

                            Study Phase : IND Enabling

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Lantern Gets IND Approval for LP-184 Trial in Resistant NSCLC Cases

                            Details : LP-184 is a lethal small molecule that induces DNA double strand breaks upon bioactivation by the enzyme PTGR1 in cancer cells. It is being investigated for Treatment-Resistant NSCLC.

                            Product Name : LP-184

                            Product Type : Cytotoxic Drug

                            Upfront Cash : Inapplicable

                            May 12, 2025

                            Lead Product(s) : LP-184,Nivolumab,Ipilimumab

                            Therapeutic Area : Oncology

                            Highest Development Status : IND Enabling

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            UTR Therapeutics

                            U.S.A arrow
                            IFT FIRST
                            Not Confirmed

                            UTR Therapeutics

                            U.S.A arrow
                            IFT FIRST
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : UTRxM1-18

                            Therapeutic Area : Oncology

                            Study Phase : IND Enabling

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            UTR Submits IND for mRNA Drug Targeting c-MYC in First-in-Human Cancer Trial

                            Details : UTRxM1-18, a novel therapeutic approach for targeting c-MYC driven cancers, harnesses UTR’s proprietary Ultra-Targeted RNA platform to degrade disease-causing transcripts with ultra-high precision.

                            Product Name : UTRxM1-18

                            Product Type : Oligonucleotide

                            Upfront Cash : Inapplicable

                            May 08, 2025

                            Lead Product(s) : UTRxM1-18

                            Therapeutic Area : Oncology

                            Highest Development Status : IND Enabling

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            OBI Pharma

                            Taiwan arrow
                            IFT FIRST
                            Not Confirmed

                            OBI Pharma

                            Taiwan arrow
                            IFT FIRST
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : OBI-902

                            Therapeutic Area : Oncology

                            Study Phase : IND Enabling

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            FDA Clears IND for OBI-902 Phase 1/2 Trop-2 ADC Study by OBI Pharma

                            Details : OBI-902 is the first ADC utilizing OBI’s proprietary GlycOBI® ADC enabling technology. It is being evaluated for advanced solid tumors.

                            Product Name : OBI-902

                            Product Type : Antibody-drug Conjugate

                            Upfront Cash : Inapplicable

                            April 30, 2025

                            Lead Product(s) : OBI-902

                            Therapeutic Area : Oncology

                            Highest Development Status : IND Enabling

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Avidicure

                            Netherlands arrow
                            IFT FIRST
                            Not Confirmed

                            Avidicure

                            Netherlands arrow
                            IFT FIRST
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : AVC-S-101

                            Therapeutic Area : Oncology

                            Study Phase : IND Enabling

                            Sponsor : EQT Life Sciences

                            Deal Size : $50.0 million

                            Deal Type : Financing

                            DEALS_DEV arrow-down

                            Avidicure Launches with $50M Seed Round to Develop Cancer Antibody Therapy

                            Details : The financing aims to advance the clinical development of lead product AVC-S-101, a TROP2-targeting booster being developed for non-small cell lung cancer and multiple other cancer indications.

                            Product Name : AVC-S-101

                            Product Type : Antibody

                            Upfront Cash : Undisclosed

                            April 24, 2025

                            Lead Product(s) : AVC-S-101

                            Therapeutic Area : Oncology

                            Highest Development Status : IND Enabling

                            Sponsor : EQT Life Sciences

                            Deal Size : $50.0 million

                            Deal Type : Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Everest Medicines

                            U.S.A arrow
                            IFT FIRST
                            Not Confirmed

                            Everest Medicines

                            U.S.A arrow
                            IFT FIRST
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : EVM14

                            Therapeutic Area : Oncology

                            Study Phase : IND Enabling

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Everest Gains FDA IND Clearance for Tumor-Associated Antigen Vaccine EVM14

                            Details : EVM14 is an off-the-shelf mRNA cancer vaccine targeting multiple tumor-associated antigens & is designed to treat various cancers, including non-small cell lung cancer and head and neck cancer.

                            Product Name : EVM14

                            Product Type : Vaccine

                            Upfront Cash : Inapplicable

                            March 23, 2025

                            Lead Product(s) : EVM14

                            Therapeutic Area : Oncology

                            Highest Development Status : IND Enabling

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Kangpu Biopharmaceuticals

                            Greece arrow
                            IFT FIRST
                            Not Confirmed

                            Kangpu Biopharmaceuticals

                            Greece arrow
                            IFT FIRST
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : KPG-818

                            Therapeutic Area : Oncology

                            Study Phase : IND Enabling

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Kangpu Gets IND Approval for KPG-818 in Multiple Myeloma

                            Details : KPG-818 is a novel oral molecular glue modulator of the E3 ubiquitin ligase complex CRL4-CRBN. It is being evaluated for the treatment of relapsed/refractory multiple myeloma.

                            Product Name : KPG-818

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            February 25, 2025

                            Lead Product(s) : KPG-818

                            Therapeutic Area : Oncology

                            Highest Development Status : IND Enabling

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Tasca Therapeutics

                            U.S.A arrow
                            IFT FIRST
                            Not Confirmed

                            Tasca Therapeutics

                            U.S.A arrow
                            IFT FIRST
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : CAS 77168-63-9

                            Therapeutic Area : Oncology

                            Study Phase : IND Enabling

                            Sponsor : Regeneron Ventures

                            Deal Size : $52.0 million

                            Deal Type : Series A Financing

                            DEALS_DEV arrow-down

                            Tasca Therapeutics Launches with $52M Series A to Develop Oncology Inhibitors

                            Details : The financing aims to advance the clinical development of company lead program, CP-383, which is bieng evaluated for the treatment of multiple cancers.

                            Product Name : CP-383

                            Product Type : Other Small Molecule

                            Upfront Cash : Undisclosed

                            December 10, 2024

                            Lead Product(s) : CAS 77168-63-9

                            Therapeutic Area : Oncology

                            Highest Development Status : IND Enabling

                            Sponsor : Regeneron Ventures

                            Deal Size : $52.0 million

                            Deal Type : Series A Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            Kivu Bioscience

                            U.S.A arrow
                            IFT FIRST
                            Not Confirmed

                            Kivu Bioscience

                            U.S.A arrow
                            IFT FIRST
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : KIVU-107

                            Therapeutic Area : Oncology

                            Study Phase : IND Enabling

                            Sponsor : Organovo Holdings

                            Deal Size : $92.0 million

                            Deal Type : Series A Financing

                            DEALS_DEV arrow-down

                            Kivu Bioscience Raises $92M to Advance Antibody-Drug Conjugates

                            Details : The financing will aims to support the clinical development of multiple antibody-drug conjugate (ADC) programs, which include KIVU-107. It is being evaluated for the treatment of neoplasms.

                            Product Name : KIVU-107

                            Product Type : Other Large Molecule

                            Upfront Cash : Undisclosed

                            October 28, 2024

                            Lead Product(s) : KIVU-107

                            Therapeutic Area : Oncology

                            Highest Development Status : IND Enabling

                            Sponsor : Organovo Holdings

                            Deal Size : $92.0 million

                            Deal Type : Series A Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth